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ABSTRACT
ARSENIC-INDUCED DEVELOPMENTAL CHANGES IN THE LIVER AND
ADULT CARDIOVASCULAR DISEASE
Ntube Nini Olive Ngalame
July 28, 2011
Chronic arsenic exposure is associated with increased cardiovascular disease
(CVD). Prenatal arsenic exposure at 49 ppm arsenic accelerates atherosclerosis
/
underlying CVD in ApoF - mice, but the mechanism is unknown. This dissertation
examines the mechanisms by which prenatal arsenic exposure accelerates
atherosclerosis. Arsenic is a hepatotoxicant, and liver disease increases
atherosclerosis risk. I hypothesized that prenatal arsenic exposure alters liver
development and primes the liver for susceptibility to other environmental insults,
predisposing to liver disease and accelerated atherosclerosis in ApoF/- mice.
I showed that prenatal arsenic exposure caused subtle but significant liver
damage in 10 and 24 week old ApoE-1- mice, thus increasing the risk of
atherosclerosis. This arsenic-induced liver injury was characterized by increased
basal levels of plasma ALT and AST (circulating markers of liver damage), and
IL-6 (pro-inflammatory cytokine).
Determination of the effects of prenatal arsenic exposure on Hsp70 and Hsc70
expression during pre- and postnatal development (GD18, and 3, 10 and 24
weeks) showed that Hsp70 was induced at age 3 and 10 weeks, but returned to
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unexposed levels by 24 weeks, thus indicating a temporal state of stress.
However Hsc70 expression was not altered at any of these ages. Determination
of Hsp70 and Hsc70 expression in isolated liver cell types showed that Hsp70 is
expressed only in the liver hepatocytes, while Hsc70 is expressed in all liver cell
types. It is likely that stressed hepatocytes can release excess Hsp70 into the
circulation, thus contributing to increased atherosclerosis as reported in the
literature. Hsp70 induction was also associated with increased CpG site
methylation at +503 to +856 bp, thus indicating epigenetic change.
Lastly, I showed that prenatal and "whole-life" arsenic exposures at lower
exposures (4.9 and 1 ppm arsenic) increased atherosclerotic lesion formation in
aortic aches, which was associated with altered plasma triglyceride and
cholesterol. However, there was no difference in lesion formation between
prenatal and "whole-life" exposures. Both exposure types also increased plasma
cytokine/chemokine expression, thus indicating inflammation which is proatherogenic. Thus, infants are at high risk of developing atherosclerosis even at
very low exposure levels.
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CHAPTER I

GENERAL INTRODUCTION

Arsenic in drinking water
Inorganic arsenic is a naturally occurring element and contaminated drinking
water is a major route of exposure. Contamination of drinking water by arsenic is
a major worldwide public health problem. Both the world health organization
(WHO) and the United States Environmental Protection Agency (USEPA)
decreased the maximum contaminant level (MCl) for arsenic in drinking water
from 50 IJg/l to 10 IJg/l to more sufficiently protect public health. However, there
are many areas around the world (United States inclusive) with drinking water
arsenic levels exceeding 10 1J9/l, and very high levels (sometimes> 300 IJg/l)
occur in Bangladesh, Taiwan, India, Chile and Argentina (Ahmed et aI., 2006;
Nordstrom, 2002). In this dissertation, drinking water arsenic was used as a route
of arsenic exposure.

Arsenic and atherosclerosis
Chronic ingestion of arsenic contaminated drinking water is associated with a
variety of human diseases. Inorganic arsenic is an established human
carcinogen causing cancer of the skin, lung and bladder. However, arsenic is
also atherogenic, although the atherogenic effect of arsenic is less well
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established. Accumulating evidence from both epidemiological and experimental
animal studies show that arsenic exposure causes cardiovascular disease
(CVD). Epidemiological studies in the endemic area of Taiwan show a doseresponse effect of arsenic exposure and atherosclerosis (Chen et aI., 1996;
Tseng, 2008; Wang et aI., 2007). Furthermore, epidemiologic studies in
populations with high arsenic exposures show increased incidence of CVD which
include carotid atherosclerosis (Wang et aI., 2002), hypertension (Chen et aI.,
1995) and ischemic heart disease (Hsueh et aI., 1998). Even in areas where
arsenic levels are much lower, for example the United States, arsenic exposure
is associated with mortality from arterial disease (Engel and Smith, 1994).
Atherosclerosis underlies most CVD which is the leading cause of death in the
world. There is a strong correlation between arsenic exposure and
atherosclerosis as demonstrated by epidemiological studies in adults (Tseng,
2008;Wang et aI., 2007) and experimental animal models (Srivastava et aI.,
2007;Srivastava et aI., 2009). The induction of atherosclerosis by drinking water
arsenic is dose-dependent with exposures as low as 1 ppm and 250 ppb arsenic
reported to induce the disease in mice (Lemaire et aI., 2011 ;Srivastava et aI.,
2009). However, the exact mechanism by which arsenic causes atherosclerosis
is not clearly understood. In this dissertation, the possible mechanisms of
arsenic-induced atherosclerosis were determined.
Accumulating data suggest that early life exposures may playa significant role in
the onset of environmental adult diseases (Barker, 2007). A role for prenatal
arsenic exposure in the development of arterial disease is suggested by reports
2

of myocardial infarction in infants from mothers who consumed water with high
levels of arsenic in Chile (Rosenberg, 1974; Rosenberg, 1973). Indeed, prenatal
exposure to arsenic accelerated atherosclerosis in ApoF'- mice, even without
high fat diet (Srivastava et aI., 2007), which is usually requisite for early
atherosclerosis in this strain. Mice exposed to arsenic (49 ppm arsenic) prenatal
developed >2-fold lesions at 10 and 16 weeks of age, compared to mice exposed
to tap water while prenatal. These lesions were located in the aortic roots, as well
as the aortic arch. Thus, these results suggest that prenatal arsenic exposure
may cause irreversible changes that predispose to development of
atherosclerosis in adult life. However, it is not determined if the induction of
atherosclerosis by prenatal arsenic exposure is dose-dependent. In this
dissertation, the dose-response effects of prenatal arsenic exposure in the
induction of atherosclerosis was determined.

Liver disease and atherosclerosis
Although atherosclerosis is a disease of the vasculature, disease modifying risk
may be derived from distal sites such as the liver. Indeed, underlying nonalcoholic fatty liver disease (NAFLO) has been shown to be a risk factor for
developing atherosclerosis in humans (Brea et aI., 2005; Targher et aI., 2004)
and is independent of other risks associated with chronic liver disease (e.g.
metabolic syndrome) (Targher et aI., 2006). Several epidemiology studies show
that nonalcoholic fatty liver disease (NAFLO) is associated with increased risk of
carotid atherosclerosis (Brea et aI., 2005; Targher et aI., 2004; Targher et aI.,
2006). Furthermore, some studies (Bellentani et aI., 2008) indicate that elevated
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liver enzymes in the plasma (e.g. AL T, AST) are risk factors for coronary events,
including atherosclerosis, and appear independent of traditional risk factors.
Although the mechanism by which liver disease modulates atherosclerosis is not
fully understood, inflammation (Kugelmas et aI., 2003; Schindhelm et aI., 2007)
and abnormal lipid metabolism (Adiels et aI., 2006) that occur in liver disease
have been proposed to contribute to atherogenesis.
The liver is a known target organ of arsenic toxicity. In humans, chronic arsenic
exposure causes hepatic abnormalities, such as hepatomegaly, non-cirrhotic
fibrosis, and portal hypertension (Santra et aI., 1999; Mazumder, 2005). Chronic
arsenic exposure has also been shown to cause liver diseases in animal models
(Santra et aI., 2000). Exposure to arsenic was also reported to induce liver
cancer and other cancers as well in mice after prenatal exposures (Waalkes et
aI., 2003;Waalkes et aI., 2004; Waalkes et aI., 2006). In this dissertation, the
hypothesis that prenatal arsenic exposure causes basal- or worsens liver
damage was tested. in the ApoF/- mouse model.

Atherosclerosis and inflammation
Atherosclerosis is a multifactorial and complex disease. Atherosclerosis results
from the process of a combination of hyperlipidemia and inflammation. ApoE-1mice are constitutively hyperlipidemic, but the source of inflammation is not
known. Accumulating evidence from many studies shows that inflammation plays
a central role in the formation of atherosclerotic plaque. During atherogenesis,
there is sub-endothelial retention of cholesterol-rich lipoproteins which lead to
endothelial activation. Lipoprotein in the sub-endothelial space is susceptible to
4

various modifications including oxidation, enzymatic cleavage, and aggregation,
which render these particles pro-inflammatory. Monocytes are rapidly recruited to
regions of lipoprotein retention in the intima and transform into macrophages.
The macrophages take up oxidized lipids and transform into foam cells. These
cholesterol-rich macrophages secrete pro-inflammatory cytokines and enhance
lesion formation and atherogenesis. As the atherosclerotic plaque evolves,
macrophages are joined by other inflammatory cells (T cells, dendritic cells,
neutrophils, mast cells) and local smooth muscle cells that contribute to the
cellular environment of the plaque. Genetic deletion of chemokines and cytokines
such as MCP-1 and IL-6 in mice decreases atherosclerotic lesion formation (Gu
et aI., 1998; Schieffer et aI., 2004). Increased expression of cytokines and
chemokines is reported to be a pro-atherogenic effect of arsenic exposure in vitro
(Lee et aI., 2005), in vivo (Srivastava et aI., 2009) and in humans (Wu et aI.,
2003). In this dissertation, the role of cytokine and chemokine expression as a
pro-atherogenic effect of prenatal arsenic exposure was determined. In addition
to cytokines and chemokines mediating inflammatory response during
atherogenesis, heat shock protein 70 (Hsp70) is also implicated in atherogenesis
as will be discussed below.

Arsenic and Heat shock protein 70
Heat shock proteins (HSPs) are stress proteins which function as molecular
chaperones under physiological conditions, and prevent protein aggregation
under stress conditions (Gething and Sam brook, 1992). Hsc70 and Hsp70 are
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members of the HSPA family of HSPs. Hsp70 is the inducible form of heat shock
protein 70 which is expressed at low levels under physiological conditions, but
induced when cells are stressed (e.g. heat shock, oxidative stress, toxic metals)
in order to provide cell survival. Hsc70 is constitutively expressed and functions
as a molecular chaperone assisting in protein folding. Arsenic exposure induces
the expression of Hsp70 in vitro and in vivo. In addition to the expression of
Hsp70 in cells and tissues during stress, stressed cells can also release Hsp70
into the circulation in membrane-bound subcellular particles called exosomes
(Asea, 2007). Exosomal Hsp70 expression can activate immune cells such as
macrophages to secrete TNF-a and thus provide an inflammatory stimulus for
atherogenesis (Vega et aI., 2008). Accumulating evidence implicates the role of
Hsp70 in atherosclerosis, with Hsp70 expression increased in atherosclerotic
lesion sites (Lu and Kakkar, 2010) and also in plasmas of patients with
atherosclerosis (Wright et aI., 2000; Zhu et aI., 2003). However, it is not clearly
understood if circulating Hsp70 has a cytoprotective or cytotoxic role in
atherogenesis (Bielecka-Dabrowa et aI., 2009). In this dissertation, the effects of
arsenic exposure on circulating exosomal Hsp70 expression were determined.

Arsenic and DNA methylation
It is well established that arsenic has epigenetic potential affecting DNA
methylation and histone modifications, thus regulating gene expression. Arsenic
can alter genome-wide DNA methylation or gene-specific methylation (Reichard
and Puga, 2010). Arsenic-induced global DNA hypomethylation and promoter
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region hypermethylation have been implicated in arsenic carcinogenesis
(Reichard and Puga, 2010). In addition to DNA methylation, histone modifications
are also epigenetic marks that modulate gene expression. Arsenic has been
shown to alter histone methylation and acetylation (Ramirez et aI., 2008; Zhou et
aI., 2008). Thus, in this dissertation, the epigenetic effects leading to altered gene
expression by arsenic exposure in the ApoE-1- mouse model was determined.
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CHAPTER II
PRENATAL ARSENIC EXPOSURE INDUCES SUBTLE POSTNATAL
HEPATIC DAMAGE AND SYSTEMIC INFLAMMATION ASSOCIATED WITH
ACCELERATED ATHEROSCLEROSIS IN APOE-1- MICE

Introduction

Atherosclerosis is a complex process of a combination of hyperlipidemia and
inflammation. ApoF'- mice are constitutively hyperlipidemic, but the source of
inflammation in the arsenic-exposed mice is not known. We hypothesize that
prenatal arsenic exposure primes the liver to a pro-inflammatory state which
worsens liver disease upon stimulation, and provides an inflammatory stimulus
for atherosclerosis. Microarray analyses of both mRNA and microRNA of livers of
10 week old mice showed that prenatal arsenic exposure increased the
expression of the pro-inflammatory cytokine TNF-a postnatally (States et aI.,
2009), thus suggesting a state of pro-inflammation.
The risk of developing liver disease from environmental exposure (e.g. arsenic)
can be modified by other conditions such as other environmental or genetic
factors. An environmental exposure can result in physiological/biochemical
changes in the liver that are pathologically inert, but that can sensitize the liver to
hepatotoxicity caused by a second agent. An example of this "2-hit" hypothesis

8

was shown by enhanced lipolysaccharide (LPS)-induced liver injury in mice
chronically exposed to arsenic postnatally However, whether prenatal arsenic
exposure modifies the risk of developing liver damage owing to other insults has
not been determined.
The purpose of the current study was to test the hypothesis that prenatal arsenic
exposure may also sensitize the liver to damage caused by a second hit, and
thus provide the stimuli for accelerated atherosclerosis. To test this hypothesis,
the LPS challenge assay was used to determine the effect of prenatal arsenic
exposure on LPS-induced liver damage.
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Materials and Methods

Animals and treatment
ApoE-1- C57BLl6J mice (B6.129P2-ApoEtm1 Unc/J, Jax Labs, Bar Harbor, ME)
were housed in a pathogen-free barrier facility accredited by the Association for
Assessment and Accreditation of Laboratory Animal Care, and procedures were
approved by the local Institutional Animal Care and Use Committee. Pregnant
mice were given tap water (for controls) or water containing 85 mg/L NaAs0 2 (49
ppm arsenic) on gestation day (GO) 8 - GD18. Their male offspring were kept
until 10 and 24 weeks old. In some of the mice, experimental liver damage was
induced by challenging them with LPS. LPS is a Gram-negative bacterial wall
product that is often elevated in systemic blood during liver disease, (Li and
Diehl, 2003) and is employed in basic research as a model toxicant to the liver.
Mice were given a bolus injection of LPS (10 mg/Kg) intraperitoneally (IP). This
dose of LPS (serotype 055:B5, batch 075K4038; Sigma St. Louis, MO) has been
determined to cause moderate liver damage with no signs of toxicity to other
target organs (Arteel et aI., 2008). Twenty-four hours after LPS injection, mice
were anesthetized with pentobarbital (150 mg/Kg). Blood was withdrawn by
cardiac puncture and citrated plasma was stored at -80°C for further analysis.
Portions of liver tissue were frozen immediately in liquid nitrogen while others
were fixed in 10% neutral buffered formalin or frozen-fixed.
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Histopathological analysis
Liver tissues from 10 week old arsenic-exposed and unexposed mice and from
mice that were dissected 24 h after LPS challenge were fixed in 10% neutral
buffered formalin and embedded in paraffin. The paraffin-embedded liver
sections were cut at 5 IJm and mounted on glass slides. Sections were
deparaffinized and stained with hematoxylin and eosin (HIE) for histological
assessment. Neutrophil accumulation in the livers was assessed by staining
tissue sections for chloroacetate esterase (CAE), using a napthol AS-D
chloroacetate esterase kit (Sigma, St. Louis MO). Results were analyzed by
counting the number of CAE positive-stained cells per 1000 hepatocytes.

Determination of plasma AL T and AST
Blood obtained from 10 and 24 week old arsenic-exposed and unexposed mice
and from mice that were dissected 24 h after LPS challenge was centrifuged at
4,600 rpm to collect plasma. Plasma levels of alanine aminotransferase (ALT)
and aspartate aminotransferase (AST) were determined enzymatically using the
commercial kit purchased from Infinity Liquid Reagents (Thermo Electron
Corporation, Pittsburg).

Determination of plasma IL-6 and TNF-a
Blood obtained from cardiac puncture of 10 week old arsenic-exposed and
unexposed mice and from mice that were dissected 24 h after LPS challenge
was centrifuged at 4,600 rpm to collect plasma. Plasma expression of the pro-
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inflammatory cytokines TNF-a and IL-6 was measured by ELISA (R & 0
Systems, Minneapolis, MN).

Western blot analysis
Frozen livers from 10 week old arsenic-exposed and unexposed mice and from
mice that were dissected 24 h after LPS challenge challenge were homogenized
in SDS lysis buffer (10 mM Tris-HCL pH 7.4,1 mM EDTA, 0.1 % SDS, 1 mM
PMSF, 1 I-Ig/mL aprotinin, 1 I-Ig/mL leupeptin, and 1 I-Ig/mL pepsatin). Liver
homogenates were centrifuged and the supernatant obtained. Protein
concentrations were determined by bicinchoninic acid protein assay (Thermo
Scientific, Rockford, IL).
Proteins (20 I-Ig) were separated by sodium dodecyl sulphate polyacrylamide gel
electrophoresis (SDS-PAGE). Proteins were transferred to nitrocellulose
membrane and blots were probed with rabbit monoclonal TNF-a antibody
(1:1000) overnight at 4°C (Cell Signaling Technology Inc., Danvers, MA).
Membranes were incubated with corresponding rabbit secondary antibodies
bound to horse radish peroxidase (HRP). Bound antibodies were visualized using
enhanced chemiluminescence plus substrate (GE Healthcare Bio-Sciences
Corp., Piscataway, NJ), and visualized directly on a Storm Phosphoimager in
blue flourescence mode (Molecular Dynamics, Sunnyvale, CA). Bands were
quantitated using Image Quant software.
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Statistical analysis
Data are expressed as mean ± SEM. Comparisons among groups were
performed using one-way ANOVA and student's t-test.
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Results

Effects of arsenic exposure on liver damage
The effects of arsenic on basal and LPS-induced liver damage was analyzed by
histologic assessment for necroinflammation and neutrophil infiltration. HIE
staining of livers of 10 week old mice showed that arsenic exposure did not
cause major macroscopic changes in liver histology in the absence or presence
of LPS (Fig. 2.1 A). LPS injection also did not produce any major macroscopic
changes in hepatic histology.
Chloroacetate esterase staining for neutrophil infiltration showed that arsenic
alone did not significantly increase hepatic neutrophil infiltration (Fig. 2.1 Band
C). LPS alone caused a robust infiltration of neutrophils in the liver. Arsenic preexposure did not enhance LPS-stimulated neutrophil infiltration.

Response of plasma AL T and AST to arsenic and LPS
The effect of arsenic exposure and LPS on circulating enzyme markers of liver
injury was also determined. Prenatal arsenic exposure alone significantly
increased plasma AL T and AST by a factor of - 2 in livers of 10 week old mice
(Fig. 2.2 A), and of -1.5 in livers of 24 week old mice (Fig. 2.2 B), thus indicating
modest liver damage. As expected, LPS alone caused liver injury, as indicated
by a significant increase in plasma ALT and AST by a factor of - 2 and 3
respectively in livers of both 10 and 24 week old mice. Arsenic alone did not
significantly enhance LPS-stimulated liver damage at either age.
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Figure 2.1. Effects of prenatal arsenic exposure and LPS on liver histology
of 10 week old mice. Ten week old prenatal arsenic-exposed and unexposed
mice were injected with LPS as described in Materials and Methods. Mice were
killed 24 h after LPS injection. Formalin-fixed liver sections were stained with HIE
for necroinflammation, and CAE for neutrophil infiltration. Data are mean ± SEM.
a=p<0 .05 Panel A: Representative photographs of HIE stains; 200x. Panel B:
Representative photographs of CAE stains; 200 x. Panel C: Quantitation of CAE
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Figure 2.2. Effects of prenatal arsenic exposure and LPS on circulating
plasma markers of liver damage in 10 and 24 week old mice. Ten (A) and 24
(8) week old prenatal arsenic-exposed and unexposed mice were injected with
LPS as described in Methods. Twenty-four hours after LPS injection , the mice
were harvested and the plasma ALT and AST levels were analyzed . a=p<O .03
compared to the absence of arsenic. b=p<O.06 compared to the absence of
arsenic. c=p<O .05 compared to the absence of LPS . Data are mean ± SE. n=6-8
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Response of plasma IL-6 and TNF-a to arsenic and LPS
Basal levels of plasma IL-6 were higher in mice with prenatal arsenic exposure
(Fig. 2.3 A). In contrast, basal level of plasma TNF-a was not changed by arsenic
exposure (Fig. 2.3 B). LPS injection produced a robust inflammatory state as
indicated by the increased levels of plasma TNF-a and IL-6. Arsenic preexposure appeared to enhance TNF-a and IL-6 expression owing to LPS
injection, but data failed to achieve statistical significance. However, arsenic preexposure produced quite robust TNF-a response in 3 out of 6 mice, and IL-6
response in 2 out of 6 mice, indicating animal to animal variability.

Response of hepatic TNF-a to arsenic and LPS
Prior work on microarray analysis of mRNA and miRNAs of livers of 10 week old
mice showed that prenatal arsenic exposure increased the TNF-a proinflammatory pathway (States et aI., 2009a). Thus, I determined the effect of
arsenic exposure and LPS challenge on hepatic TNF-a expression by western
blot analysis. The data in figure 1.4 show that whereas hepatic TNF-a expression
was significantly increased by LPS injection, arsenic exposure did not alter the
basal or LPS-stimulated induction of TNF-a expression.
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Discussion
In this study, the "2-hit" hypothesis was tested to determine whether prenatal
arsenic exposure enhances liver damage owing to a secondary insult. This
hypothesis was tested by challenging prenatally arsenic exposed or unexposed
mice with a bolus dose of LPS and sacrificing the mice 24 h later. Liver damage
can be assessed histopathologically for necroinflammation and neutrophil
infiltration. Several studies show that liver damage caused by arsenic exposure is
characterized by abnormal histological changes. Epidemiology studies
(Mazumder, 2005) report the manifestation of hepatic histological abnormalities
by arsenic exposure. In animal studies, arsenic-induced liver damage (3.2 and
200 ppm arsenic) is characterized by abnormal histological changes in the livers
of C3H and 8alb/c mice after several months of exposures (Santra et aI., 2000;
Santra et aI., 2000; Wu et aI., 2008). In fact, Santra et al. 2000 reported that
chronic arsenic exposure for up to 9 months did not cause changes in liver
histology, but the appearance of histological changes occurred only after 12
months of exposure. Exposure to 49 ppm arsenic in drinking water for 7 months
enhanced LPS-induced hepatic histological changes by increasing
necroinflammatory foci (Arteel et aI., 2008).
There is also a strong correlation between liver disease and atherosclerosis.
Epidemiological studies show that the severity of histological features of NAFLD
is strongly correlated with carotid atherosclerosis (8rea et aI., 2005;Targher et
aI., 2006). In the present study, prenatal arsenic exposure alone, or in the
presence of LPS did not cause any detectable macroscopic changes in the liver
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as assessed by HIE and CAE staining. These results are different from those
reported in the literature probably because the arsenic exposure was very brief
(only 10 days prenatal) as compared to the chronic (7 or 12 months) postnatal
exposures used in the reported studies. Furthermore, I used ApoF'- mouse in
C57BLl6 background strain which is genetically different form the C57BLl6
mouse strain used in the Arteel et aL study. In addition, there are differences in
atherosclerosis induction between prenatal- and postnatal arsenic exposures,
with chronic postnatal exposure inducing more lesion formation (3-5 fold) than
prenatal exposures (2 fold) (Srivastava et aI., 2007;Srivastava et aI., 2009).
Circulating concentrations of the liver transaminases, ALT and AST have been
used as markers of NAFLD. Several epidemiologic and animal studies show that
arsenic-induced liver damage is characterized by elevated plasma liver enzymes.
Elevated plasma AL T and AST are seen with liver damage after chronic arsenic
exposure in both humans (Mazumder, 2005) and in experimental animals (Santra
et aI., 2000; Wu et aI., 2008). Chronic arsenic exposure for 7 months did not
alter plasma liver enzymes, but enhanced elevated plasma liver enzymes
induced by LPS (Arteel et aI., 2008). There is also a strong correlation between
NAFLD and plasma liver enzymes and increased risk of atherosclerosis.
Elevated plasma AL T predicts coronary heart disease events in humans,
independent of traditional CVD risk factors (Adibi et aI., 2007; Schindhelm et aI.,
2007). Other epidemiological studies (Brea et aI., 2005;Targher et aI., 2006)
show that elevated ALT and AST increase the risk of developing atherosclerosis.
Consistent with what is reported in the literature, I have shown that prenatal
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arsenic exposure caused slight but significant elevated plasma AL T and AST
postnatally (10 and 24 weeks) thus suggesting liver damage. This is the first
animal study to report arsenic-induced plasma AL T and AST in an
atherosclerosis animal model. These data indicate a correlation between liver
disease (as indicated by elevated plasma liver enzymes) and increased
incidence of atherosclerosis, consistent with human epidemiology. Whereas it is
not quite clear why the effects of prenatal arsenic exposure on plasma liver
enzymes were attenuated by LPS challenge instead of the anticipitated
enhancement, there exists a possible explanation. It is possible that the dose of
LPS used for the study is high such that it masks the mild effects of prenatal
arsenic exposure. This LPS dose was used for the Arteel et al. 2008 study with
chronic arsenic exposure.
Liver injury can also be characterized by hepatic and/or systemic inflammation.
LPS is known to induce inflammatory cytokine expression. Chronic arsenic
exposure is reported to increase hepatic TNF-alpha and IL-6 expression
associated with liver damage (Oas et aI., 2005; Wu et aI., 2008). In addition,
epidemiological studies show that cord blood TNF-a is associated with arsenic
exposure (Ahmed et aI., 2011). In the present study, I determined the effect of
prenatal arsenic exposure on the basal and LPS-stimulated expression of proinflammatory cytokine IL-6 and TNF-a. The data show that whereas LPS injection
increased systemic TNF-a and IL-6 expression, prenatal arsenic exposure alone
increased systemic IL-6 but not TNF-a expression. Arsenic exposure did not
significantly enhance LPS-induced expression of these cytokines. However,
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there appeared to be an interaction effect between arsenic exposure and LPS, as
indicated by the apparent increase in cytokine expression in the arsenic/LPS
group when compared to LPS alone. Although arsenic did not significantly
increase the LPS-stimulated levels of, IL-6 and TNF-a, there was animal
variability in response, with about half of the mice showing very elevated
response. Prior work showed that prenatal arsenic exposure increased the TNFa pro-inflammatory pathway as analyzed by microarray analysis of mRNA and
miRNA of livers of 10 week old mice (States et aI., 2009). However, western blot
analysis showed that prenatal arsenic exposure did not increase hepatic TNF-a
expression. These data are inconsistent with previous reports probably due to
the short-term exposure I did, compared to chronic exposure. The absence of a
significant arsenic effect upon LPS injection might be because the cytokines
have passed their peak levels in the plasma at the 24 h time point.
In summary, this study demonstrates that exposure to arsenic prenatally causes
subtle but significant liver damage observed postnatally at 10 weeks that
continues at least until 24 weeks. This liver damage is characterized by
increased plasma ALT and AST levels, with no macroscopic histologic changes.
Arsenic exposure increased systemic- but not hepatic inflammation. We don't yet
know if the damage is permanent or temporal. Thus, further studies are required
for later time points.
In conclusion, these results suggest that prenatal arsenic exposure induces
subtle but significant liver damage, characterized by only elevated plasma liver
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enzymes and systemic inflammation. The observed liver damage is associated
with increased atherosclerosis observed in the ApoF'- mouse model.
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CHAPTER III
DELAYED TEMPORAL INCREASE OF HEPATIC HSP70 IN APOE
KNOCKOUT MICE AFTER PRENATAL ARSENIC EXPOSURE
Introduction

Epidemiological studies indicate chronic arsenic exposure is associated with high
risk of CVD (States et aI., 2009). Atherosclerosis underlies most CVD, which is
the leading cause of mortality worldwide. Arsenic exposure in drinking water
accelerates atherogenesis in experimental animal models, (Simeonova et aI.,
2003) and the induction is dose-dependent (Srivastava et aI., 2009). However,
the mechanism of arsenic-induced atherogenesis is unknown.
Gestation is a critical period of development. Arsenic readily crosses the placenta
in humans and rodents (Concha et aI., 1998; Lindgren et aI., 1984). Thus,
developmental arsenic exposures can predispose to adult diseases as indicated
by induction of liver cancers in adult male mice (Waalkes et aI., 2003). Reports of
myocardial infarction in infants whose mothers consumed water with high levels
of arsenic in Chile (Rosenberg, 1973; Rosenberg, 1974) suggest a role for
prenatal arsenic exposure in the development of CVD. Indeed, prenatal arsenic
exposure accelerated atherosclerosis in ApoE-1- mice without high fat
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diet, which is usually requisite for early atherosclerosis in this strain (Srivastava
et aL, 2007).
Although atherosclerosis is a vascular disease, the atherogenic stimulus can
come from distant sites, including the liver. Epidemiology studies show that liver
disease is an independent risk factor for carotid atherosclerosis (Brea et aL,
2005; Targher et aL, 2006), and that elevated liver enzymes in the plasma (e.g.
ALT, AST) are risk factors for coronary events (Bellentani et aL, 2008). Arsenic is
toxic to the liver, causing liver diseases in humans and animal models (Guha
Mazumder, 2001; Santra et aL, 2000). It is likely that prenatal arsenic exposure
affects liver development predisposing to adult chronic disease. The hypothesis
that prenatal arsenic exposure altered developmental programming of the liver of
ApoE-1- mice with accelerated atherosclerosis was tested by microarray analyses
of both mRNA and microRNA in newborn and 10 week old mice (States et aL,
2009). The data showed several differentially expressed genes including
constitutive (Hsc70) and inducible (Hsp70) heat shock protein 70; age being the
major influence on gene expression thus reflecting developmental changes
(States et aL, 2009).
HSPs are stress proteins which are constitutively expressed at low levels, but upregulated under stress conditions (e.g. heat shock, toxic metals, oxidative stress)
in order to confer protection against such stressors. HSPs function as molecular
chaperones under physiological conditions, and prevent protein aggregation
under stressed conditions (Gething and Sambrook, 1992). Hsc70 and Hsp70 are
members of the HSPA family of HSPs. In spite of numerous in vitro data showing
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Hsp70 induction by arsenic, there are very few in vivo data. Therefore, it is still
unclear how Hsp70 expression is regulated postnatally after prenatal arsenic
exposure.
One of the mechanisms by which the expression of a gene can be altered is by
epigenetic regulation, particularly DNA methylation. Arsenic interferes with
genome-wide and site-specific DNA methylation (Reichard and Puga, 2010).
Thus, exposure to arsenic prenatal is likely to cause epigenetic alterations,
particularly DNA methylation which can lead to altered gene expression.
In this study, the hepatic expression of Hsp70 and Hsc70 during prenatal and
postnatal development was determined in mice prenatally exposed to arsenic. In
addition, the epigenetic effects of arsenic were determined. This is the first study
to determine how the expression of Hsp70 changes during early postnatal
development following prenatal arsenic exposure.
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Material and Methods

Chemicals
Sodium arsenite (NaAs02 ) was obtained from Sigma Chemical Co. (St. Louis,
MO). Adenosyl-L-methionine, S-[methyl-3H]; (SAM [3HD, (specific activity 81.9
Ci/mmol) was purchased from Perkin-Elmer, Inc. (Boston, MA). Protease
inhibitors were purchased from Sigma Chemical Co. (St. Louis, MO) and Fisher
Scientific (Rockford, IL).

Animal treatment and sample collection
ApoF'- mice were housed and bred under pathogen-free conditions in controlled
temperature and 12 h lightl12 h dark cycle. Animal care was provided following
the guidelines of the Association for the Accreditation of Laboratory Animal Care.
Prior to treatment, all mice were maintained on standard chow diet and tap water
as previously described (Srivastava et aI., 2007). Briefly, mice were bred by
housing 2-4 females with each male. Females were checked daily for the
presence of a vaginal plug. The presence of a plug was designated gestational
day 0 (GDO), and the female was assumed pregnant. Pregnant mice were
housed separately, and were given drinking water containing 85 mg/L NaAs0 2
(49 ppm arsenic) or tap water (for controls) ad libitum from GD 8 through GD18.
During prenatal arsenic exposures, arsenic containing water was changed twice
weekly. Dams were allowed to give birth (GD18-GD21) and male offspring were
maintained on tap water and normal chow ad libitum until sacrificed at 3, 10 and
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24 weeks of age. Liver samples were frozen at -80 cc until analysis. GD18 dams
were also sacrificed and maternal and fetal livers were obtained and stored
frozen at -80 cC. All mice were anesthetized with pentobarbital (150 mg/Kg)
before sacrifice. Studies were performed under protocols approved by the
University of Louisville Institutional Animal Care and Use Committee.

Measurement of hepatic arsenic levels by inductively coupled plasmamass spectrometry (ICP-MS)
Total arsenic which would include inorganic and organic forms was determined
by ICP-MS. Access to the ICP-MS instrument is available through the Center for
Regulatory, Environmental and Analytical Metabolomics at University of
Louisville on a fee per service basis. We have used this instrument to measure
arsenic in cell cultures (McNeely et aI., 2008). A portion of the frozen maternal
and GD18 fetal liver (300-600mg) was transferred to 2 mL acid washed (0.1 M
HN03 acid) centrifuge tubes and digested in 350 IJL concentrated nitric acid
overnight. One hundred IJL of digested sample was transferred to 10 mL acid
washed microwavable digestion tubes in triplicates, and every 3rd sample from
each group was spiked with 5 ng arsenic standards (SPEX CertiPrep, Metuchen,
NJ). The samples were microwave digested at 150 cC for 10 min using
Automated Microwave Synthesis Workstation. Residues were removed by
centrifugation, and 1.9 mL of 18 Mohm water containing 10 ppb internal standard
solution was added in to every sample to give 5% HN0 3 acid. Each sample (1.5
mL) was transferred to acid washed polypropylene deep-well 96 well plates for
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ICP-MS analysis using Thermo Electron ICP-MS, X-Series. Blank was
concentrated nitric acid. Results are expressed in ng arsenic/g wet weight.

Isolation of proteins from total liver homogenates
Frozen livers from G018 fetuses, and 3, 10 and 24 week old mice were
homogenized in ice-cold radioimmunoprecipitation assay (RIPA) buffer (50 mM
Tris-HCL pH7.4, 1% NP-40, 0.25% Na-deoxycholate, 150 mM NaCI, 1 m M
EOTA, 1 mM phenylmethylsulphonyl fluoride (PMSF), 1 I-Ig/mL aprotinin, 1 I-Ig/mL
leupeptin, 1 I-Ig/mL pepsatin, 1 mM Na3V04 and 1 mM NaF) or SOS lysis buffer
(10 mM Tris-HCL pH7.4, 1 mM EOTA, 0.1 % SOS, 1 mM PMSF, 1 I-Ig/mL
aprotinin, 1 I-Ig/mL leupeptin, and 1 I-Ig/mL pepsatin). Liver homogenates were
centrifuged and the supernatants obtained as protein extracts. Protein
concentrations were determined by bicinchoninic acid protein assay (Thermo
Scientific, Rockford, IL).

Extraction of cytosolic and nuclear fractions
Livers of 3 and 10 week old arsenic-exposed and unexposed mice were
subjected to cytosolic and nuclear extractions. Frozen livers (0.1 g) were ground
in liquid nitrogen and transferred to a dounce homogenizer. Using pestle B,
tissues were homogenized in 700 I-IL of ice-cold Polyamine A buffer (0.34 M
sucrose, 13.3 mM Tris-HCI pH 7.5, 13.3 mM NaCI, 0.1 %

~-mercaptoethanol,

53

mM KCI, 2 mM EOTA, 0.5 mM EGTA, 0.5 mM Spermidine, 0.5 mM Spermine, 1
mM PMSF, 1 I-Ig/mL aprotinin, 1 I-Ig/mL leupeptin, 1 I-Ig/mL pepsatin, and
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phosphatase inhibitor) about 15 strokes. Oounce homogenizer was rinsed with
300

~L

of polyamine A buffer. The suspension was transferred to 1.5 mL

centrifuge tubes and centrifuged at 4500 g for 15 min, at 4°C. The supernatant,
which is the cytosolic fraction, was removed and transferred to a new tube and
stored at -80°C
The nuclear pellet was resuspended in 300

~L

of Polyamine A buffer + 2.1 M

sucrose solution (mixed in equal ratios), and the suspension was layered on top
of 200

~L

of Polyamine A buffer + 2.1 M sucrose solution (mixed in equal ratios)

in centrifuge tubes. Tubes were centrifuged in a Beckman TLA 120.2 rotor at
95,000 x g, for 1 h, at 4°C. The supernatant was removed and nuclear pellet
was lysed in 200
glycerol, 5 mM
leupeptin, 1

~L

of Buffer B (20 mM Hepes, 1 M NaCI, 5 mM MgCI 2 , 12 %

on, 2 M Urea, 1 mM PMSF, 1 ~g/mL aprotinin, 1 ~g/mL

~g/mL

pepsatin, and phosphatase inhibitor) and incubated shaking

for 30 min at 4°C. Nuclear lysate was centrifuged at 14,000 x g, for 15 min at
4°C and supernatant was collected and stored at -80°C as nuclear extract.
Protein concentrations in cytoplasmic and nuclear extracts were measured using
Bio-Rad protein assay.

Western blot analysis

Proteins (20 - 25

~g)

were separated by sodium dodecyl sulphate

polyacrylamide gel electrophoresis (SOS-PAGE) and transferred unto
nitrocellulose membranes. Membranes were incubated with primary antibodies
including mouse monoclonal, and rabbit monoclonal Hsp70 antibodies (1: 1000,
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overnight at 4°C; Enzo Life Sciences International, Inc., Plymouth Meeting, PA,
and Epitomics Inc., Burlingame, CA); rat monoclonal Hsc70 antibody (1:1000,1 h
at 4°C; Enzo Life Sciences International, Inc., Plymouth Meeting, PA); rabbit
polyclonal Hsf1 antibody (1 :500, 24 h at 4°C; Cell Signaling Technology Inc.,
Danvers, MA); and rabbit ployclonal Nrf2 antibody (1: 1000 overnight at 4°C; Cell
Signaling Technology Inc., Danvers, MA). Membranes were incubated with
corresponding mouse, rabbit, and rat secondary antibodies bound to HRP. The
membranes were incubated with ECl or ECl plus substrate (GE Healthcare BioSciences Corp., Piscataway, NJ). ECl membranes were exposed to Kodak XAR
x-ray film. Signals on ECl plus membranes were visualized directly on a Storm
Phosphoimager in blue flourescence mode (Molecular Dynamics, Sunnyvale,
CA). Bands were quantitated using Image Quant software.

Global DNA methylation assay
Genomic DNA was isolated from frozen liver tissues of GD18 fetuses and 3, 10
and 24 week old mice by the salting out method. Global DNA methylation was
determined by the methyl acceptance assay as described (Xie et aI., 2007) with
some modifications. Briefly, 2 IJg DNA was incubated for 2 h at 37°C in a 30 IJl
reaction mixture containing 1.25 IJM (3 IJCi) [3H]-SAM, 4 units of CpG Methylase
(M. ss I) (New England Biolabs, Inc., Beverly, MA), 10 mM OTT, Tris-EDTA
buffer (100 mM Tris, 10mM EDTA, pH 8.0) and 100 mM NaCI. The reaction was
stopped on ice and split in two aliquots of 15

~L.

Each aliquot was transferred

onto a Whatman DE81 filter to bind DNA. Bound DNA was washed on a filtration
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funnel connected to a vacuum source three times with 5 mL of 0.5 M phosphate
buffer (pH 7.0) , once with 5 mL of 70% ethanol and twice with 5 ml of absolute
ethanol. The filter was dried and 5 mL of liquid scintillation cocktail (Beckman
Coulter, Fullerton , CA) was added . Bound radioactivity was measured by
scintillation counting on a Tri-Carb 291 OTR liquid scintillation analyzer (pelkin
Elmer, Boston , MA)

Promoter region and CpG island methylation of Hsp 70

Genomic DNA was isolated from livers of 10 week old arsenic-exposed and
unexposed mice and 400 ng DNA was subjected to bisulfite treatment using EZ
DNA Methylation Direct Kit (Zymo Research Corp. , Irvive CA) according to
manufacturer's protocol. PCR primers were designed using the MethPrimer
software (http://www.urogene.org/methprimer/index1 .html) which designs
oligonucleotide primers for methylation PCR. Primers were designed to amplify 5
regions of Hsp70 CpG island , which spans the promoter region and 66 % of the
body of the gene. Primers were also designed to amplify untreated (original)
DNA. Bisulfite-treated DNA (50 ng) and untreated DNA (100 ng) was amplified by
PCR using High Fidelity Platinum Taq DNA Polymerase (Invitrogen Corp. ,
Carlsbad , CA) according to manufacturer's protocol (see Table 2.1 for PCR
primer sequences) . PCR products were visualized on a 1.5 - 2 % agarose gel
(based on PCR product size) and single distinct bands were observed. PCR
products were purified using Multiwell PCR Purification Kit (Qiagen Inc. ,
Valencia, CA) and sequenced using nested oligonucleotides. In this method ,
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sodium bisulfite converts all unmethylated cytosines to uracil residues, while 5methyl cytosine is resistant to conversion. PCR amplification then converts the
uracils to thymidines. After sequencing, unmethylated cytosines are detected as
thymidines, thus making it possible for determination of site-specific methylation.

Statistical analysis
Data are expressed as mean ± SEM. Comparisons among groups were
performed using one way ANOVA and student's t-test.
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Table 2.1. Oligonucleotides used in amplifying and sequencing Hsp70 in
bisulfite treated DNA.
Region

Oligonucleotide Type
PCR
(Tm 50 DC)

=

1

Sequencing

(Tm

PCR
58 DC)

=

2

Sequencing

(Tm

PCR
58 DC)

=

3

Sequencing

(Tm

PCR
55 DC)

=

4
Sequencing

(Tm

PCR
60 DC)

=

5

Sequencing

Oligonucleotide Sequence
Fw: 5'·TAGTATTTTTAGGAGTTGATTTTTAATAGT·3'
Rv: 5'·TTATCTCTAAATAAAACCAAATTTAATTCT·3'
Fw: 5'·TTAGGAGTTGATTTTTAATAGT·3'
Fw: 5'·TTTGGAGAGTTTTGGATAAG·3'
Rv: 5'·CCAAATTTAATTCTAAATAACTATC·3'
Fw: 5'·ATTTAGAATTAAATTTGGTTTTATTTAGAG·3'
Rv: 5'·TATAATTCACCTACACCTTAAACTTATC·3'
Fw: 5'·TTAAATTTGGTTTTATTTAGAG·3'
Fw: 5'·GTAATTTTTTTAGGAGTATTTTTG·3'
Fw: 5'·GATTTGGGTATTATTTATT·3'
Rv: 5'·CACCACCTAAAAAAACCAATAC·3'
Fw: 5'·ATGAAGTATTGGTTTTTTTAGGTGGT ·3'
Rv: 5'·ATCCTTCTT ATACTTCCTCTTAAACTCCT·3'
Fw: 5'·TATTGGTTTTTTTAGGTGGT·3'
Fw: 5'·GAAGATGAAGGAGAT·3'
Fw: 5'·GGTAGGTTATTAAGGA·3'
Rv: 5'·CTTATACTTCCTCTTAAACTC·3'
Fw: 5'·GAAGTATAAGAAGGATATTAGTTAGAATAA·3'
Rv: 5'·AAAAAAATCCTACAACAACTTCTACAC·3'
Fw: 5'·AGAAGGATATTAGTTAGAATAA·3'
Fw: 5'·TAGTATTTAGGTTAGTTTGGAG·3'
Rv: 5'·TCCTACAACAACTTCTACAC·3'
Fw: 5'·TGTAGAAGTTGTTGTAGGATTTTTTTAA·3'
Rv: 5'·AATAACCTCCTAACACTTATCCAACAC·3'
Fw: 5'·AAGTTGTTGTAGGATTTTTT·3'
Fw: 5'·GGTTATTTTGATGGGGGATAA·3'
Fw: 5'·GTAATTTTATTATTTTTATTAAGTAG·3'
Fw: 5'·GATAATAATTTGTTGGGG·3'
Fw: 5'·GGTAAGGTTAATAAGATTATTAT·3'
Rv: 5'·CCTCCTAACACTTATCCAAC·3'
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Figure 3.1. Schematic representation of Hsp70 showing regions analyzed
for methylation studies. Red arrows indicate peR primers. Black arrows

indicate position of nested sequencing oligonucleotides.
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Results

GD18 fetal and maternal hepatic arsenic content
To determine whether maternal arsenic exposure actually reaches the fetus, I
measured the maternal and GD18 fetal total arsenic content by ICP-MS. Very
little arsenic was detected in unexposed maternal and fetal livers (Fig. 3.2), the
source of arsenic being the mouse diet. In contrast, inorganic arsenic exposure
increased liver arsenic levels -55 fold (1165 ± 179 ng/g wet weight) and - 26-fold
in feta livers (350 ± 20 ng/g wet weight). The concentration of arsenic detected in
the maternal livers was similar to the -1.5 mg/kg reported in liver biopsies of
humans with chronic arsenic exposure in West Bengal (Mazumder et aI., 1998).
Thus, my animal exposure model anchors the results to this human population
with relatively high arsenic exposure

(~1 00

ppm arsenic). These data indicate

that maternal arsenic exposure crossed the placental barrier and reached the
fetal liver as reported by others (Jin et aI., 2006; Lindgren et aI., 1984).

Hepatic Hsp70 and Hsc70 expression during course of postnatal
development
Hsp70 is a stress response protein whose expression is induced during stress
(e.g. heat shock or toxic metals). Thus, I determined by western blot the effect of
prenatal arsenic exposure on Hsp70 expression at different stages of
development, in GD18 fetuses (Day 0), and 3 (Day 21), 10 (Day 70), and 24
week old mice (Day 168). The results show that Hsp70 expression was not
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Figure 3.2. ICP-MS analysis of GD18 fetal and maternal hepatic arsenic
content. A portion (300-600 mg) of the frozen maternal and GD18 fetal livers
was digested in nitric acid. Total arsenic which would include inorganic and
organic forms was determined by time of flight-inductively coupled plasma-mass
spectrometry (ICP-MS) as described in Materials and Methods. Data are
expressed as Mean ± SEM , n=3. *=p<0.02. #=p<.003
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altered at GD18 at the end of the arsenic exposure (Fig. 3.3 A). However, 21
days later, Hsp70 expression was increased by a factor of -2 in arsenic-exposed
livers. The increased expression of Hsp70 remained constant at Day 70, but
returned to unexposed levels by Day 168. These data indicate that prenatal
arsenic exposure caused a delayed temporal induction of inducible Hsp70, thus
suggesting a temporal state of stress in the livers of exposed mice.
In contrast to increased expression observed with inducible Hsp70, the
expression of constitutive Hsc70 was not altered during any stage of
development (Fig. 3 3 C). These data are consistent with constitutive nature of
Hsc70.

Global DNA methylation analysis
The effect of prenatal arsenic exposure on global DNA methylation at different
stages of development (GD18 fetuses, and 3, 10 and 24 weeks) was determined
by methyl acceptance assay. This assay uses a bacterial DNA methyltransferase
that methylates all unmethylated cytosines in DNA. In this assay, SAM labeled
with [3H] at the donated methyl group is the methyl donor. Thus, lower methyl
incorporation corresponds to higher degree of DNA methylation (i.e.
hypermethylation). In the DNA of both arsenic-exposed and unexposed mice,
incorporation of methyl groups into DNA decreased with increasing age (Fig.
3.4). Thus, liver DNA becomes hypermethylated globally as mice age. However,
prenatal arsenic exposure did not alter the global DNA methylation status at any
age.
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Figure 3.3. Western blot analyses of hepatic Hsp70 and Hsc70 expression
during course of prenatal and postnatal development. Livers of control and
arsenic-exposed mice at four stages of development (GD18 , and 3, 10 and 24
weeks) were homogenized with either SDS lysis buffer or RIPA buffer as
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described in Materials and Methods. Western blot was performed to probe for
Hsp70 and Hsc70. 14-3-3

13 was used as the loading and normalization control

for GD18 samples, while GAPDH was used as the loading and normalization
control for 3, 10 and 24 week samples. *=p<0.003. Panel A: Representative
western blot images of Hsp70 in livers of arsenic exposed and unexposed mice
sacrificed on GD18, Day 21, Day 70 and Day 168. Panel B: Densitometric
quantitation of Hsp70 at each stage of development. Panel C: Representative
western blot images of Hsc70 in livers of arsenic exposed and unexposed mice
sacrificed on GD18, Day 21, Day 70 and Day 168. Panel D: Densitometric
quantitation of Hsc70 at each stage of development.
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Figure 3.4. Analysis of global DNA methylation during course of prenatal
and postnatal development, measured by methyl acceptance assay. Higher
eH] methyl incorporation by bacterial DNA methyltransferase into unmethylated
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to Day 70. Data are mean ± SEM . n=6-9
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Methylation status of the promoter region and CpG island of Hsp70
The Methylation of DNA in the promoter region or within the body of the gene can
alter the expression of the gene. I determined if the increased Hsp70 expression
observed with prenatal arsenic exposure corresponded to differential DNA
methylation induced by arsenic exposure. The Hsp70 CpG island is 2.5 kb long
and spans through the promoter region and 66 % of the body of the gene (Fig.
3.1). Hsp70 methylation was determined in livers of 10 week old mice by bisulfite

sequencing of 5 regions spanning 1.9 kb of the CpG island (Fig. 3.1) as
described in Materials and Methods. The methylation status of analyzed regions
of hepatic Hsp 70 CpG island which includes the promoter region is shown in
Figure 3.5 A. The results are expressed as percentage CpG site methylation per
region. The data reveal that the promoter region (R1) of Hsp70 is completely
unmethylated in DNAs from both arsenic-exposed and unexposed mice.
However, analysis of regions within the body of Hsp 70 (R2 - R5) show
differential methylation patterns, with region-specific hypo- and hypermethylation.
In many instances, a CpG site is completely methylated or unmethylated (Fig. 3.5

8). Relative to controls, arsenic exposure significantly increased CpG site
methylation of Region 3 (R3 spans +503 to +856).
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Figure 3.5. Analysis of Hsp70 promoter region and CpG island methylation.
Genomic DNA was isolated from livers of 10 week old arsenic-exposed and
unexposed mice and 400 ng was subjected to bisulfite treatment for the
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determination of Hsp70 methylation as described in Methods. Data are Mean ±
SEM. *p<O.004 Panel A: Quantitation of percentage CpG site methylation per
region. Panel B: A representative sequence from R3 (n=3-5) showing methylated
and unmethylated CpG sites. Methylated cytosines are represented as dots in
the boxes, while unmethylated cytosines appear as "t".
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HSF1 and Nrf2 nuclear translocation and activation
Hsf1 and Nrf2 are transcription factors which are major regulators of Hsp70
expression. The translocation of Hsf1 and Nrf2 from cytoplasm to nucleus is
important for their activation in gene transcription. To determine if arsenic
exposure was also having an upstream effect on transcription factors regulating
Hsp70 expression, western blot analysis of cytosolic and nuclear Hsf1 and Nrf2
proteins was performed. Data revealed that a greater part of Nrf2 is located in the
cytosol, with very limited translocation to the nucleus (Fig. 3.6). Arsenic exposure
did not alter the cytosolic levels of Hsf1 and Nrf2, nor did it increase nuclear
translocation. The levels of Hsf1 in both cytosolic and nuclear fractions were very
low and almost undetectable. Absence of nuclear translocation indicates Hsf1
and Nrf2 are not activated. These data suggest the mechanism of Hsp70
induction by arsenic exposure is by other transcription factors.
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Figure 3.6. Western blot analysis of Hsf1 and Nrf2 cytosolic and nuclear
protein levels. Cytosolic and nuclear fractions were isolated from livers of 3 and
10 week old arsen ic-exposed or unexposed mice as described in Materials and
Methods. Western blot was performed to probe for Hsf1 and Nrf2. GAPDH was
used as the normalization control for cytosol ic proteins and to determine nuclear
purity, while Histone 3 was used as the normalization control for nuclear proteins
and to determine cytosolic purity. Panel A: Representative western blot images of
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cytosolic and nuclear Hsf1 and Nrf2 in livers of 3 week old arsenic-exposed and
unexposed mice. Panel B: Representative western blot images of cytosolic and
nuclear Hsf1 and Nrf2 in livers of 10 week old arsenic-exposed and unexposed
mice. Panel C: Densitometric quantitation of cytosolic and nuclear Hsf1. Panel D:
Densitometric quantitation of cytosolic and nuclear Nrf2
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Table 3.2. MiRNAs decreased by prenatal arsenic exposure and predicted
to have sites on Hsp70 mRNA as predicted by miRWalk and other
programs.
MiRNA

Target region

Mmu-miR-130a

3'-UTR

Mmu-miR-218

CDS

Mmu-miR-412

CDS

Mmu-miR-681

CDS
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Discussion
Whereas Hsc70 is a constitutively expressed molecular chaperone, Hsp70 is a
stress- inducible type which helps cells to resist stress by solubilizing denatured
protein aggregates, facilitating the restoration of the function of renatured
proteins, and transporting irreversibly damaged proteins to degradative
organelles and proteasomes (Kiang and Tsokos, 1998). This study for the first
time clearly demonstrate that prenatal exposure to inorganic arsenic results in
delayed temporal postnatal induction of the stress inducible Hsp70 gene in livers
of ApoF'- mice. Hsc70 expression did not change during any stage of postnatal
development thus confirming it is not stress inducible. The Hsp70 expression
increases several weeks after arsenic exposure is stopped and continues for
several more weeks before returning to normal levels. The increased Hsp70
expression at ages 3 and 10 weeks following prenatal arsenic exposure indicates
a temporal period of stress, and thus suggests a critical window during which
time the mice are most susceptible to other environmental insults leading to
atherosclerosis. These data suggest a low grade injury in which there is no
detectable damage at the time of arsenic exposure, but the tissue becomes
sensitized or primed for a greater detectable damage upon a second hit which
comes later in life. This hypothesis is supported by the enhanced
lipopolysaccharide-induced liver damage caused by chronic arsenic exposure
(Arteel et aI., 2008). Thus, the data in this current study suggest that Hsp 70
expression is not sufficient to be used as a biomarker of arsenic exposure as
proposed by some in vitro and vivo studies (Del Razo et aI., 2001; Han et aI.,

50

2005) owing to the absence of increased expression at the time of exposure.
Absence of G018 hepatic Hsp70 induction in our study is consistent with the
findings of Petrick et al. (Petrick et aI., 2009) who reported that microarray
analysis of G018 embryonic mouse lungs showed no alterations in Hsp70
expression following prenatal arsenic exposure. Other studies have reported
increased Hsp70 expression in vivo following arsenic exposure. Hsp70 is
reported to be induced in mouse liver by chronic low dose postnatal arsenic
exposures (Andrew et aI., 2007), and in lungs after acute subcutaneous
injections of sodium arsenite and arsenate (Liu et aI., 2001). Also, microarray
analysis of adult C3H mouse liver tumors revealed decreased Hsp70 mRNA
expression by prenatal arsenic exposure (Liu et aI., 2004). However, the
decreased Hsp70 expression was not confirmed by RT-PCR or western blot.
There is also growing evidence implicating Hsp70 in atherosclerosis (Lu and
Kakkar, 2010). Stressed cells can actively release extracellular Hsp70 (Asea,
2007) which when present in extracellular membranes can activate macrophages
to induce TNF-a expression (Vega et aI., 2008), leading to increased
inflammatory stimulus promoting atherogenesis. Importantly, Hsp70 expression
is increased in the plasmas of patients with atherosclerosis (Wright et aI., 2000;
Zhu et aI., 2003). However, it is still unclear whether circulating Hsp70 has a
cytoprotective or cytotoxic role in atherosclerosis (Bielecka-Oabrowa et aI.,
2009).Taken as a whole, these observations suggest that the stressed hepatic
cells in our mouse model may release excess Hsp70 into the circulation, thus
contributing to the observed increased atherosclerosis.
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Arsenic exposure can alter epigenetic marks, especially causing DNA
methylation alterations (Reichard and Puga, 2010). In the present study, prenatal
arsenic exposure did not alter global DNA methylation postnatally during the
course of development. This finding is consistent with the report of
hypomethylation in GC-rich regions but not globally in hepatic DNA of newborn
C3H mice exposed to arsenic prenatal (Xie et aI., 2007). The novelty of this study
is that global DNA methylation during the course of pre- and postnatal
development was determined. The findings are that global DNA methylation does
not remain constant, but increases (DNA becomes hypermethylated) with age.
Chronic postnatal arsenic exposure is reported to cause global DNA
hypomethylation in livers of adult mice and is associated with arsenic-induced
hepatocarcinogenesis (Chen et aI., 2004). The apparent difference in global DNA
methylation between my findings and that of Chen et al. can be attributed to the
difference in arsenic exposure; brief prenatal arsenic exposure versus chronic
postnatal exposure.
DNA methylation is an important epigenetic mechanism involved in altered gene
expression. For example, prenatal arsenic exposure decreased the methylation
of estrogen receptor-a promoter region of adult mouse liver leading to increased
gene expression which may playa role in arsenic-induced hepatocellular
carcinoma (Waalkes et aI., 2004). Global DNA methylation does not predict what
happens at gene-specific level. Thus, the role of DNA methylation as a potential
mechanism underlying increased Hsp70 expression was determined. The
results show that prenatal arsenic exposure did not alter Hsp70 promoter region

52

methylation, but significantly increased methylation within the body of the gene,
thus, indicating an epigenetic effect. The methylation pattern across the Hsp70
gene was also determined. The data show that Hsp70 promoter region is
generally unmethylated and that the methylation density increases in the body of
the gene, with some regions having higher methylation densities than others. It is
reported that extensive CpG methylation of a 1.2 kb region spanning the Hsp 70
transcription start site is associated with transcriptional silencing of Hsp70 genes
in several mouse cell lines in which Hsp70 expression is not activated by heat
shock (Gorzowski et aI., 1995). This report suggests that the methylation status
of Hsp70 promoter region can correlate with gene expression, with increased
methylation associated with decreased gene expression and vice versa.
However, this correlation between Hsp70 promoter region methylation status and
gene expression is not seen in my animal model. This lack of methylation
difference indicates that the underlying mechanism of Hsp70 induction is not due
to decreased Hsp70 promoter region methylation.
Hsf1 and Nrf2 are the major characterized players involved in Hsp 70
transcription. During cellular stress, Hsf1 becomes activated and trans locates
from the cytoplasm to the nucleus where it directly binds to the Hsp 70 promoter
region and induces transcription (Kiang and Tsokos, 1998). On the other hand,
Nrf2 is a transcription factor that transcriptionally activates expression of antioxidant responsive genes. Nrf2 activation also is associated with nuclear
translocation (Kobayashi and Yamamoto, 2005). Although Nrf2 does not directly
target Hsp70, activation of Nrf2 is reported to be associated with Hsp70 induction

53

(Rinaldi Tosi et aI., 2011). Hsf1 is reported to be the mechanism underlying
increased Hsp70 expression following acute arsenic treatment in vitro (Kato et
aI., 1997; Khalil et aI., 2006). However, the mechanism underlying arsenicinduced Hsp70 expression in vivo is not clearly understood, because the few
reported in vivo studies did not determine the mechanism of increased Hsp70
expression. One study (Wijeweera et aI., 2001) reports the involvement of AP-1
transcription factor activation and DNA binding in the induction of stress proteins
including Hsp70 in precision-cut rat lung slices exposed to arsenic. I also
determined whether arsenic may be causing an upstream effect in inducing
Hsp70 expression. The mechanisms underlying delayed increased Hsp70
expression following prenatal arsenic exposure might be different from that of
immediate gene induction following acute or chronic arsenic exposure.
Immediate Hsp70 induction in response to stress is usually by traditional
transcription factor activation which is a transient event. I thus propose that in
addition to altered DNA methylation within the body of Hsp70, another potential
mechanism of delayed Hsp70 induction in response to stress is the involvement
of miRNA regulation. Prior microarray analyses of miRNA in 10 week old mice
with or without prenatal arsenic exposure revealed that arsenic exposure
decreased the expression of 15 miRNAs (States et aI., 2009). Four out of the 15
decreased miRNAs (Table 3.2) have been predicted to have sites on Hsp70
mRNA 3'-untranslated region (UTR) and coding sequence (CDS) regions as
predicted by miRWalk and other programs (http://www.ma.uniheidelberg.de/apps/zmf/mirwalkl). MiRNAs are short RNA molecules, about 23
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nucleotides long that are post-transcriptional regulators of gene expression.
MiRNAs bind to complementary sequences on mRNAs, usually resulting in
translational repression and gene silencing (Bartel, 2009). These data suggest
that the decreased expression of miRNAs that target the Hsp70 mRNA results in
increased Hsp70 mRNA stability, thus leading to increased protein levels in livers
of arsenic-exposed mice. Future work will investigate regulation of the miRNAs.
In summary, the present study demonstrated that prenatal exposure to arsenic in
drinking water results in delayed temporal induction of inducible type Hsp70 in
the liver. Prenatal arsenic exposure did not alter global DNA methylation during
postnatal development. The underlying mechanism of Hsp70 induction is not by
transcription factor activation, but likely involves altered DNA methylation within
the body of the gene. Other potential mechanisms such as increased microRNA
stability might also be involved. These findings indicate that prenatal arsenic
exposure causes a low grade injury and suggest that there is a critical window
during which the liver is most sensitized to increased susceptibility to other
environmental insults, thus predisposing to liver disease and accelerated
atherosclerosis.
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CHAPTER IV
DIFFERENTIAL HSP70, HSC70, GST-ALPHA AND TNF-A EXPRESSION IN
HEPATOCYTES, KUPFFER CELLS, SINUSOIDAL ENDOTHELIAL CELLS
AND STELLATE CELLS ISOLATED FROM APOE KNOCKOUT MICE
EXPOSED TO ARSENIC PRENATAL

Introduction

Arsenic exposure alters expression of many genes in the liver which could
contribute to the development of diseases. For example, the induction of
hepatocellular cancer by prenatal arsenic exposure is associated with the altered
expression of genes related to estrogen receptor alpha function, which could
contribute to the development of cancer (Liu et aI., 2006). Furthermore, in the
prenatal arsenic-induced atherosclerosis mouse model, arsenic exposure
differentially regulates gene expression in the liver as determined by microarray
analysis of mRNA and miRNA of newborns and 10 week old mice (States et aI.,
2009). Age was the major factor for differential gene expression, with pathways
involving heat shock protein 70 (Hsp70), heat shock cognate 70 (Hsc70) and
tumor necrosis factor (TNF) increased by arsenic exposure in livers of 10 week
old mice, thus suggesting a state of stress and pro-inflammation. Western blot
analysis showed increased Hsp70 but not Hsc70 or TNF-a expression in 10
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week old arsenic exposed mice (see Chapter II and III). However, despite the
many studies that report the effects of arsenic exposure on hepatic gene
expression, it is not yet determined how arsenic affects the expression of these
genes in the different cell types that make up the liver. That is, if the arsenic
effect on a particular gene is the same in all liver cell types, or arsenic has a
preferential effect on a particular cell type.
The liver is a heterogeneous organ that is made up of different cell types which
differ in functional characteristics. The major liver cell types are the parenchymal
cells (PCs) (also known as hepatocytes, make up 70-80 % of the liver mass) and
the non-parenchymal cells (NPCs) (which are resident in or along the normal
liver sinusoid, and participate in the function of the liver). The NPCs include 3
major cell types, the Kupffer cells, endothelial cells and stellate cells (Bouwens et
aI., 1992). The Kupffer cells are specialized macrophages resident in the liver
that form part of the reticuloendothelial system. Kupffer cells function in
endocytosis, antigen processing, secretion of bioactive factors and cytotoxicity.
The sinusoidal endothelial cells (SEC) are characterized by fenestrations (pores)
which regulate transport and exchange of materials between the blood and
hepatocytes. Stellate cells (SC) are vitamin A-storing cells and constitute 5-8 %
of total liver cells. In normal liver, SC are in a quiescent state, but become
activated during liver damage to produce extracellular matrix and collagen. In this
study, the expression of selected genes in the different liver cell types was
determined; i.e. which liver cell types are expressing these genes and how
arsenic exposure alters gene expression.
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Materials and Methods

Materials
Pronase E was purchased from Merck: EMD (Gibbstown, NJ), Collagenase and
DNase were purchased from Roche Diagnostics (Indianapolis, IN), and
Nycodenz was purchased from AXIS-SHIELD (Norton, MA)

Animals and treatment
ApoF'- C57BLl6J mice were housed in a pathogen-free barrier facility accredited
by the Association for Assessment and Accreditation of Laboratory Animal Care,
and procedures were approved by the local Institutional Animal Care and Use
Committee. Pregnant mice were given tap water (for controls) or water containing

85 mg/L NaAs02 (49 ppm arsenic) on gestation days (GD) 8 - GD18. Their male
offspring were kept until 16-17 weeks old and maintained on a standard diet.

Liver perfusion and cell type isolation
Mice were anesthetized with ketamine/xylazine HCI solution (80/12 mg/kg i.m.).
A cross incision was made in the abdomen of the mouse and 20G catheter was
inserted into the inferior vena cava (IVC) and the vessel was cannulated. The
chest cavity was opened to induce backflow of blood. The liver was perfused with
EGTA-solution (137 mM NaCI, 5.4 mM KCI, 0.6 mM NaH 2P04 , 0.8 mM Na2HP0 4 ,
10 mM HEPES, 4.2 mM NaHC03 , 0.5 mM EGTA, and 4.5 mM glucose, pH 7.4)
at a rate of 5 mLlmin. The portal vein was cut and cannulated immediately, and
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the suprahepatic IVC was clamped using a vascular clamp. Liver perfusion with
EGTA solution continued until the liver became pale in color. The liver was
perfused with pronase E solution (40 mg/100 mL SC-2 solution (137 mM NaCI,
5.4 mM KCI, 0.6 mM NaH2P04, 0.8 mM Na2HP04, 10 mM HEPES, 4.2 mM
NaHC0 3 , 3.8 mM CaCI 2.2H 20, pH 7.4)) for 5 min. Perfusion with pronase E
solution was followed by 7-8 min perfusion with collagenase D solution (50
mg/120 mL SC-2 solution). A heat lamp was used throughout the perfusion
process. The liver was carefully removed and placed in a 100 mm petri dish
containing SC-2 solution on ice. The gall bladders were removed and each liver
was separately minced well to separate cells. Cells were transferred into sterile
Erlenmeyer flask and 25 mL warm (40°C) solution "D" (100 mL SC-2 + 55 mg
collagenase + 50 mg pronase + 1 mL DNase I solution (2 mg/mL Grey's
balanced salt solution B (GBSS/B)) was added per liver. Grey's balanced salt
solution B (GBSS/B) consisted of 137 mM NaCI, 5 mM KCI, 1 mM MgCI 2.6H 20,
0.3 mM MgS04.7H 20, 0.4 mM Na2HP04, 0.2 mM KH 2P0 4, 5.5 mM glucose, 2.7
mM NaHC03 , 1.5 mM CaCb.2H 20, at pH 7.35. The cells were incubated at 37°C
for 25 minutes with frequent shaking and the digested liver was filtered through a
sterile nylon mesh sheet (120 IJm) / Cell strainer (BD Falcon, 70 IJm). Samples of
50-100 uL were removed as total cell fraction and frozen. Cells were centrifuged
at 50 x g for 5 min at 4°C to separate the parenchymal cells (PCs) from the nonparenchymal cells (NPCs). The supernatant containing NPCs was removed and
placed on ice, while the hepatocyte pellet was resuspended in GBSS/B solution
and washed twice at 50 x g for 5 min at 4°C. Hepatocyte pellets were aliquoted
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and stored frozen. Each NPC fraction was transferred to 50 mL Falcon tubes and
centrifuged at 550 x g for 10 min at 4°C. The supernatant was discarded except 5
mL. The pellet was resuspended and aliquots were taken as total NPCs fraction.
Five mL GBSS/B containing 120 IJL DNAse I was added to each NPC
suspension. Suspensions from 2-4 mice of the same exposure group were
pooled in one 50 mL tube. GBSS/B was added up to 50 mL and NPCs were
centrifuged at 550 x g for 10 min at 4°C. The supernatant was discarded except 5
mL. An additional 5 mL of GBSS/B containing 120 uL of DNase I was added and
pellets were resuspended. GBSS/B was added up to 30 mL. NPCs were
subsequently separated by nycodenz gradient centrifugation. Two Nycodenz
gradients were poured in 5 mL tubes. Thirty % Nycodenz stock was made by
adding 11 g Nycodenz in 33 mL of GBSS/A (5 mM KCI, 1 mM MgCI 2 .6H 2 0, 0.3
mM MgS0 4 .7H 2 0, 0.4 mM Na 2 HP04 , 0.2 mM KH 2 P04 , 5.5 mM glucose, 2.7 mM
NaHC03 , 225 mg/L CaCI 2 .2H 20, pH 7.35) and the solution was filtered through
0.22 IJm filter. Nycodenz 17.5 % was made by mixing 13.5 mL 30 % nycodenz +
10 mL GBSS/B, while 10.8 - 11 % Nycodenz was made by mixing 30 mL cell
pellets with 13.5 mL of 30 % Nycodenz. To pour the Nycodenz gradients, the
cells (20-22 mL) were layered first, followed by 11-12 mL of 17.5 % Nycodenz
from the bottom. Lastly, 2.5-3 mL of GBSS/B was carefully added on top of the
cell layers. The tubes were centrifuged at 1450 x g, for 20 min at 20°C with the
break set off (i.e deceleration set to 1 and acceleration to about 5). Stellate cells
(=3-5 mL I 15 mL tube) were collected from the white layer under the clear layer
of GBSS/B solution using a 5 mL pipette and transferred to new 50 mL tube. The
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layer (interface) beneath the white layer containing Kupffer cells (KC) and
sinusoidal endothelial cells (SEC) was collected (20-25 mL) and transferred to
new 50 mL tubes. The pellet at the bottom contained red blood cells. G8SS/8
was added up to 50 mL overall volume to stellate cells (pooled cells from the two
15 mL tubes) and centrifuged at 550 x g for 10 min at 4°C. Cells were
resuspended in 1 mL G8SS/8, transferred into 1 mL tubes and centrifuged again
to collect pellets. To the fraction containing KC and SEC, G8SS/8 was added to
50 mL mark to dilute the Nycodenz. Tubes were centrifuged at 900 x g for 10 min
at 4°C, and supernatant was removed. Cell pellets were resuspended in 2 mL of
RPMI 1640 and plated in 35 mm petri dish to separate the KCs from SECs.
Plates were incubated for 20 min at 3rC, 95-100 % humidity and 5 % C02 for
Kupffer cells to adhere to plastic. After incubation, supernatant containing SEC
was removed and pooled in a 15 mL tube. Adhered Kupffer cells were washed
with G8SS/8 once and cells were collected in 1 mL tube and centrifuged to
obtain pellets. SECs were centrifuged at 900 x g for 10 min at 4°C. Supernatant
was removed and SEC pellet resuspended in 1 mL G8SS/8 and centrifuged to
obtain pellets. Quality control was performed for hepatocytes by light microscopy,
and stellate cells by fluorescent microscopy. All cells were stored frozen at -80°C
for further studies

Isolation of total proteins from isolated liver cell types
Isolated liver cell fractions (total cell fractions, total NPCs, hepatocytes, KCs,
SECs and SCs) were sonicated in SDS lysis buffer (10 mM Tris-HCL pH7.4, 1
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mM EDTA, 0.1 % SDS, 1 mM PMSF, 1 IJg/ml aprotinin, 1 IJg/ml leupeptin, and
1 IJg/ml pepstatin and phosphatase inhibitor). Cell Iysates were centrifuged at
14,000 x 9 for 30 min at 4 DC. The supernatant was transferred into a new tube
and protein concentrations were determined with the Bio-Rad Bradford protein
assay (Bio-Rad, Hercules, CA)

Western blot analysis
Proteins (20 IJg) were separated by SDS-PAGE. Proteins were transferred to a
nitrocellulose membrane, and blocked with 5 % non-fat dry milk to prevent nonspecific antibody binding. Membranes were incubated with primary antibodies
including mouse monoclonal Hsp70 and rat monoclonal Hsc70 antibodies
(1:1000, overnight at 4 DC; Enzo Life Sciences International, Inc., Plymouth
Meeting, PA); rabbit GST-a (1 :5000, 1 h at RT; a gift from Dr. Russel Prough at
the University of louisville); and rabbit polyclonal TNF-a antibody (1 :1000
overnight at 4 DC; Cell Signaling Technology Inc., Danvers, MA).; and rabbit
polyclonal TNF-a (1:1000 overnight at 4 DC; Cell Signaling Technology Inc.,
Danvers, MA). Membranes were incubated with corresponding mouse, rabbit,
and rat secondary antibodies bound to HRP. The membranes were analyzed by
ECl plus substrate (GE Healthcare Bio-Sciences Corp., Piscataway, NJ).
Signals on ECl plus membranes were visualized directly on a Storm
Phosphoimager in blue flourescence mode (Molecular Dynamics, Sunnyvale,
CA). Protein bands were quantitated using the Image Quant software.
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Statistical analysis
Data are expressed as mean ± SEM. Comparisons between groups were
performed using student's t-test.
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Results

Effects of prenatal arsenic exposure on heat shock protein expression in
isolated liver cell types
I have previously shown (in chapter III) that prenatal arsenic exposure causes a
delayed temporal increase in hepatic inducible Hsp70 expression during the
course of postnatal development of ApoE-1- mice. The increased expression was
observed at 3 and 10 weeks of age, but returned to normal control levels at 24
weeks. Conversely, the expression of constitutive Hsc70 was not altered by
arsenic exposure during the course of postnatal development. However, it is
unknown which liver cell types express these heat shock proteins. Therefore, in
this study, I determined the expression of Hsp70 and Hsc70 in liver cell types
(PCs (hepatocytes) and NPCs (KC, SEC, and SC) isolated from 16 -17 week old
ApoF/- mice following prenatal arsenic exposure. The results discussed here are
those obtained from hepatocyte fractions and separated individual NPCs. I could
not obtain data for the total cell fractions and total NPCs because these samples
were fast degrading, and thus unreliable. The results (Fig. 4.1) show that
whereas the inducible Hsp70 is cell type-specific and expressed only in the
parenchymal cells, the constitutive Hsc70 is expressed in both parenchymal and
non-parenchymal cells. However, prenatal arsenic exposure did not alter the
expression of Hsp70 at 16-17 weeks of age. Conversely, the expression of
Hsc70 was significantly decreased in arsenic-exposed PCs (p<O.01) at 16-17
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Figure 4.1. Effects of prenatal arsenic exposure on heat shock proteins in
isolated liver cell types. Isolated liver cell types from perfused livers of 16-17
week old mice following prenatal arsenic exposure were lysed in SDS lysis buffer
for total protein isolation. Western blot analysis was performed to probe for
Hsp70 and Hsc70. Data are mean ± SEM , n=6-9. *=p<O.01 Error bars represent
SEM of samples analyzed from the same exposure group. Note that perfused
livers from 2-4 mice were pooled to obtain each sample of Kupffer cells (KC) ,
sinusoidal endothelial cells (SEC) and stellate cells (SC) . Panel A:
Representative western blot images. Panel B: Densitometric quantitation of
Hsp70 and Hsc70.
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weeks of age. Hsc70 expression was also decreased in NPCs although not
statistically significant.

Effects of prenatal arsenic exposure on antioxidant responsive genes in
isolated liver cell types
I also determined the effect of prenatal arsenic exposure on glutathione-stransferase (GST) alpha expression which is an antioxidant responsive gene.
The results (Fig. 4.2) show that GST-alpha expression is also cell type-specific,
with expression occurring only in parenchymal cells and not in non-parenchymal
cells. However, prenatal arsenic exposure did not alter the expression of GSTalpha at 16-17 weeks of age.

Effects of prenatal arsenic exposure on inflammatory cytokines in isolated
liver cell types
TNF-alpha is a pro-inflammatory cytokine. Therefore, effect of prenatal arsenic
exposure on TNF-alpha was determined. My first observation was that TNFalpha is expressed only in NPCs and not in PCs (Fig. 4.3). In addition, TNF-alpha
expression was higher in Kupffer cells than in the sinusoidal endothelial cells,
and much lower in stellate cells. Secondly, prenatal arsenic exposure did not
alter the expression of TNF-alpha in any of the cell types at 16-17 weeks of age.
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Figure 4.2. Effects of prenatal arsenic exposure on oxidative stress
response in isolated liver cell types. Isolated liver cell types from perfused
livers of 16-17 week old mice following prenatal arsenic exposure were lysed in
SDS lysis buffer for total protein isolation . Western blot analysis was performed
to probe for GST-alpha. Data are mean ± SEM , n=6-9. Error bars represent SEM
of samples analyzed from the same exposure group. Note that perfused livers
from 2-4 mice were pooled to obtain each sample of Kupffer cells (KC),
sinusoidal endothelial cells (SEC) and stellate cells (SC) . Panel A:
Representative western blot images. Panel B: Densitometric quantitation of GSTalpha.
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Figure 4.3. Effects of prenatal arsenic exposure on inflammation in isolated
liver cell types. Isolated liver cell types from perfused livers of 16-17 week old
mice following prenatal arsenic exposure were lysed in SDS lysis buffer for total
protein isolation . Western blot analysis was performed to probe for TNF-alpha .
Data are mean ± SEM , n=6-9. Error bars represent SEM of samples analyzed
from the same exposure group. Note that perfused livers from 2-4 mice were
pooled to obtain each sample of Kupffer cells (KC) , sinusoidal endothelial cells
(SEC) and stellate cells SC) . Panel A: Representative western blot images.
Panel B: Densitometric quantitation of TNF-alpha .
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Discussion
The liver is a heterogeneous organ consisting of different cell types, including PC
(hepatocytes) and NPC. The major sub-cell types of NPC include KC, SEC and
SC. The liver's primary role in detoxification takes place within the PCs, whereas
the NPCs provide physical and biochemical structure to the liver. Although there
are several reports of altered gene expression in the liver in response to toxic
agents including arsenic, there is little knowledge about which liver cell types are
expressing these genes. In addition, it is unknown how the different liver cell
types are affected during toxicity. The effects of prenatal arsenic exposure on the
hepatic expression of Hsp70 and Hsc70 during the course of postnatal
development (G018, and 3 week, 10 and 24 week of age) in ApoE-1- mice were
shown in Chapter III. It was shown that prenatal arsenic exposure did not alter
Hsp70 expression at G018 (when arsenic exposure is removed), but induced
Hsp70 expression at 3 and 10 weeks of age. However, at 24 weeks of age,
Hsp70 expression returned to control levels. Conversely, the expression of
Hsc70 was not altered at any of the ages studied. Thus, in this study, I
determined the expression of these heat shock proteins in liver cell types isolated
from perfused livers of mice exposed to arsenic prenatal. My results show that
Hsp70 is expressed only in the hepatocytes and was not altered by arsenic
exposure at age 16 weeks. Conversely, Hsc70 is expressed in all liver cell types,
and expression was decreased in hepatocytes by arsenic exposure at age 16
weeks. These data are different from my previous observations of the expression
of the proteins at different life stages.
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The reason for these differences can be attributed to the difference in the ages
studied. These new data indicate that the 16 weeks age fell in the descending
part of the Hsp70 expression curve. Furthermore, the difference in Hsc70 data
also shows that time or age is an important factor when studying toxicity. It is
possible that the reduced expression of Hsc70 resulted secondarily from the
hepatic injury caused by prenatal arsenic exposure. A similar observation was
reported in an experimental endotoxic shock model where hepatic Hsc70
expression was decreased when D-galactosamine-sensitized mice were exposed
to lipopolysaccharide (Morikawa et aI., 1998). The expression of Hsc70 observed
in all liver cell types is not surprising since Hsc70 is a molecular chaperone that
is constitutively expressed in cells. Under physiological conditions, Hsc70
functions in regulating protein folding, protein translocation across membranes
and degradation of aged proteins (Kiang and Tsokos, 1998). Thus, Hsc70
expression occurs in all liver cell types since all cells make proteins. Conversely,
Hsp70 is a stress-response protein whose expression is induced when cells are
stressed (e.g. by heat shock, toxic metals and oxidative stress). Expression of
Hsp70 in only hepatocytes suggests that these are the cells that respond to
stress when the liver is exposed to toxic agents.
Arsenic exposure is also known to result in oxidative stress, leading to the
upregulation of antioxidant responsive genes. GSTs are antioxidant responsive
proteins which function in the detoxification of endogenous compounds and
xenobiotics. GSTs conjugate these compounds to reduced glutathione and
facilitate their excretion from the body. The current study shows that GST-alpha
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is expressed only in the hepatocytes and not in NPCs. Furthermore, prenatal
arsenic exposure did not alter the expression of GST-alpha at 16-17 weeks of
age, which is different from increased GST-alpha activity in livers of mice
chronically exposed to arsenic (Santra et aL, 2000). This difference can be
attributed to the fact that I looked at GST-alpha protein levels long after the
exposure rather than measured activity following a chronic exposure. The
hepatocyte-specific expression of GST-alpha is consistent with the fact that the
hepatocytes perform the detoxification of xenobiotics in the liver.
Chronic arsenic exposure is reported to increase hepatic TNF-alpha and IL-6
expression associated with liver damage (Oas et aL, 2005; Wu et aL, 2008). Prior
work showed that prenatal arsenic exposure increased tumor necrosis factor
pathway as determined by microarray analysis of miRNA and mRNA of livers of
10 week old mice (States et aL, 2009), thus suggesting a state of proinflammation. Confirmation of the microarray data by western blot analysis (see
Chapter II) showed that hepatic TNF-alpha expression was not altered by
prenatal arsenic exposure at 10 weeks of age. Thus, it was determined whether
the expression of TNF-alpha is differentially affected in the liver cell types
isolated from perfused livers of 16-17 week old mice with prenatal arsenic
exposure. The data show that TNF-alpha is expressed only in the NPCs, with
Kupffer cells showing the highest expression, and stellate cells the lowest.
Furthermore, prenatal arsenic exposure did not significantly increase the
expression of TNF-alpha at 16-17 weeks of age which is consistent with the data
obtained in Chapter II. Therefore, these data suggest that the livers of prenatally
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arsenic-exposed mice are not in a state of pro-inflammation at 10 or 16-17
weeks. Kupffer cells are the principal cells that mediate inflammatory responses
in the liver, and have been reported to contribute to injury. These data explain the
lack of LPS response observed in Chapter II. Activated Kupffer cells release
several mediators including TNF-alpha which can act directly on hepatocytes to
cause cell death, or indirectly through activation of other cells (Roberts et aI.,
2007). Sinusoidal endothelial cells and stellate cells are also reported to secrete
cytokines (Bouwens et aI., 1992).
In summary, this study has shown that Hsp70 is expressed only in the
hepatocytes and its expression is not altered by prenatal arsenic exposure at 1617 weeks of age. On the other hand, Hsc70 is expressed in all liver cell types,
and its expression is decreased by prenatal arsenic exposure in the hepatocytes
of 16-17 week old mice. GST-alpha is expressed only in the hepatocytes, and its
expression is not affected by prenatal arsenic exposure. Lastly, TNF-alpha is
expressed only in the non-parenchymal cells, and prenatal arsenic exposure did
not affect its expression at 16-17 weeks of age. Collectively, based on my
experimental data and other reported studies, it is now clear that the deleterious
effects of arsenic exposure depends on many factors, including exposure levels,
exposure types, and time point or age studied. Therefore, it is important to
consider critically all the above-mentioned factors when studying arsenic toxicity
in animal models.
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CHAPTER V
PRENATAL ARSENIC EXPOSURE AT LOW EXPOSURE LEVELS
INCREASES ATHEROSCLEROTIC LESION FORMATION AND PLASMA
INFLAMMATORY CYTOKINES/CHEMOKINES RELATED TO
CARDIOVASCULAR DISEASE

Introduction

Prior studies demonstrated that prenatal arsenic exposure in drinking water at an
exposure level of 49 ppm arsenic accelerated atherosclerosis in ApoE-1- mice,
even without high fat diet which is usually requisite for early atherosclerosis in
this strain (Srivastava et aI., 2007). The 49 ppm arsenic exposure reflects
exposures in populations with high arsenic levels. It still remains unclear if
prenatal arsenic exposure can induce atherosclerosis in populations with low
arsenic levels. For postnatal exposures, exposures as low as 1 ppm arsenic
(Srivastava et aI., 2009) and 250 ppm arsenic (Lemaire et aI., 2011) have been
reported to increase atherosclerosis. It is thus necessary to determine if there is
a threshold dose for the induction of atherosclerosis by prenatal arsenic
exposure. Gestation is a period of sensitivity to initiation of adult atherosclerosis.
However, it is likely that humans would have full life exposure. Our transplacental
protocol of exposing pregnant ApoF/- dams to inorganic arsenic (49 ppm arsenic)
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in drinking water from gestation days 8 to 18 does not duplicate typical human
exposure. The predictive adaptive response was a term coined by Gluckman and
Hanson (Gluckman and Hanson, 2004) for the phenomenon in which a fetus
responds to changes in its intrauterine environment by making adaptations to
improve its immediate chances of survival. These adaptations are often
reversible, but can be irreversible if the environmental changes persist. In this
way, the fetus prepares itself for life in an extrauterine environment, e.g. low food
availability or high levels of stress (de Boo and Harding, 2006). If the predicted
environment is different from the actual environment into which the fetus is born,
it may result in disease. Thus, based on the predictive adaptive response
phenomenon, it is unknown whether exposure to arsenic prenatally will protect or
enhance atherosclerosis promoted by arsenic exposure.
Despite the clear epidemiologic links between arsenic and an increased risk of
atherosclerosis, the mechanisms by which arsenic enhances atherosclerosis are
unclear. Atherosclerosis is a multi-factorial and complex disease process.
Accumulating evidence from many studies indicates inflammation plays a central
role in atherosclerotic plaque formation (see Chapter I).
Thus, in this study, the effect of lower exposure levels of arsenic on
atherosclerosis was examined. In addition, the effects of "whole-life" arsenic
exposures in the development of atherosclerosis was investigated by determining
whether prenatal exposure protects against or enhances later life exposures.
Lastly, the pro-atherogenic effects of arsenic on inflammation and circulating
Hsp70 were also determined.
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Materials and Methods

Animal housing and treatment protocols
ApoF'- mice were housed and bred under pathogen-free conditions in controlled
temperature and 12 h lightl12 h dark cycle following the guidelines of the
Association for the Accreditation of Laboratory Animal Care. Prior to treatment,
all mice were maintained on standard chow diet and tap water as previously
described (Chapter II). Studies were performed under protocols approved by the
University of Louisville Institutional Animal Care and Use Committee.
In one group, pregnant mice were maintained on tap water (controls) or tap water
containing 8.5 mg/L (4.9 ppm arsenic) or 1.7 mg/L (1 ppm arsenic) NaAs0 2 ad
libitum from gestation days (GO) 8-18 (prenatal only exposure), and the offspring

were sacrificed at 10 or 16 weeks. In another group, the arsenic exposure
continued throughout gestation (from G08), birth and postnatally until offspring
were sacrificed at 10 or 16 weeks ("whole-life" exposure). Summary of treatment
protocols is as follows.
Protocol A: n = 7; Control, 0 ppm arsenic, 10 or 16 weeks
Protocol B: n = 7-9; 4.9 ppm arsenic prenatal only, 10 or 16 weeks
Protocol C: n =11-13; 4.9 ppm arsenic "whole life", 10 or 16 weeks
Protocol 0: n = 7; 1 ppm arsenic prenatal only, 16 or 24 weeks
Protocol E: n = 10; 1 ppm arsenic "whole life" 16 weeks
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Throughout the course of study all mice were maintained on standard chow (not
high in fat), and anesthetized with pentobarbital (150 mg/Kg) at the end of
treatment protocol. Blood and tissues were removed for analysis.

Atherosclerotic lesion analysis
For morphometric analysis, the entire aorta from the heart extending to 5 mm
after bifurcation of the iliac arteries and including the subclavian right and left
common carotid arteries was removed for lesion analysis en face. The aorta was
cleaned of peri-adventitial tissue under a dissecting microscope. The aorta was
dissected longitudinally to expose the intimal surface. The aortic arch was
stained with Sudan IV for the presence of lipids. The aortic arch was defined as
the region from ascending arch to 3 mm distal to subclavian artery (Srivastava et
aI., 2007). Percent lesion area was calculated using Image J software (National
Institute of Health, USA).
For the analysis of aortic valves, the upper section of the heart tissue was frozen
in Tissue Tek OCT (Sakura, CA, USA) reagent and serial cryosections of 8 IJm
thickness were taken from the origin of the aortic valve leaflets throughout the
aortic sinus. A total of 37 serial sections from the aortic sinus from each mouse
were collected. Sections were stained with oil red 0 and counterstained with
hematoxylin. Mean lesion area was calculated from the analysis of digital images
obtained from 10 serial sections from each mouse using Metamorph imaging
software.
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Plasma lipids and cytokinelchemokine analysis
Blood was withdrawn by cardiac puncture. Disodium EDTA (3 mM) and sodium
citrate were used as anti-coagulants. The blood was centrifuged at 2000 xg for
20 min at room temperature to obtain plasma. Plasma cholesterol, phospholipids
and triglycerides were measured using commercial kits from Wako Chemicals
USA (Richmond, VA). For cytokine measurements, plasma was centrifuged at
13,000 xgfor 5 min to clear plasma. Plasma cytokine levels (IL-1

~,

IL-6, IL-10,

MCP-1, KC, VEGF, and where indicated IFNy, TNF-a, MIP1-a and GM-CSF)
were measured using an immunoassay multiplex bead based kit (Millipore
Corporation, Billerica, MA) on a Luminex 200™ IS (Luminex Corporation, Austin
TX).

Exosome isolation
Circulating exosomes were isolated from plasma as described (Li et aI., 2009)
with some slight modifications. Eight hundred IJL of RPMI-1640 medium was
added to 200 IJL of plasma, and the sample was centrifuge at 2,000 xgfor 10
min at 4°C. Supernatant was transferred to 15 mL tubes, avoiding pellet at the
bottom or fat at the top if present. Supernatant was diluted to 10 mL with cold
PBS, centrifuged at 10,000 xg for 20 min at 4°C to remove large debris. Samples
were transferred to ultracentrifuge tubes and centrifuged at 100,000 xg for 2 h
using Beckman Ti type 70.1 rotor to pellet exosomes. Exosomes were
resuspended in 50 IJL phosphate buffered saline (PBS) and protein concentration
was determined using Bradford assay (Bio-Rad Corp., Hercules, CA).
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Western blot analysis
Proteins (10 - 15 I-Ig) were separated by SDS-PAGE. Proteins were transferred
to nitrocellulose membrane and blots were probed with rabbit monoclonal Hsp70
antibody (1 :1000) overnight at 4°C (Epitomics Inc., Burlingame, CA), and with
corresponding rabbit secondary antibody linked to HRP. The bound antibodies
were visualized using ECl plus substrate (GE Healthcare Bio-Sciences Corp.,
Piscataway, NJ), and visualized directly on a Storm Phosphoimager in blue
flourescence mode (Molecular Dynamics, Sunnyvale, CA). Protein bands were
quantitated using the Image Quant software.

Statistical analysis
Data are expressed as mean ± SEM. Comparisons among groups were
performed using one way ANOVA and student's t-test. However, Wilcoxon
ranked sum test was used when the distribution was not normal.
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Results

Average daily arsenic water consumption and effects of arsenic exposure

on body weight
During the "whole-life" arsenic exposure studies, the daily arsenic drinking water
consumption was measured during a period of one week (mice ranged from 7-10
weeks old), in order to determine the average arsenic intake by mice. The results
(Table 5.1) show that mice exposed to 4.9 ppm arsenic in drinking water
consumed 30 ng As/day/mouse compared to 5.7 ng As/day/mouse consumed by
mice exposed to 1 ppm arsenic. However, breeder mouse with 12 day old pups
consumed up to 87 ng As/day/mouse at 4.9 ppm arsenic exposure.
For the most part, except for the 4.9 ppm arsenic exposure prenatal, arsenic
exposure did not alter the body weights of mice at the end of the study (Table
5.2). However, prenatal arsenic exposure at 4.9 ppm arsenic significantly
decreased the body weight of 10 week old mice compared to the unexposed
age-matched controls.

Prenatal arsenic exposure at lower exposures results in increased
atherosclerotic lesion formation

Prenatal arsenic exposure at 49 ppm arsenic exposure accelerates
atherosclerosis in ApoF'- mice (Srivastava et aI., 2007). However, the doseresponse effect of prenatal arsenic exposure on the development of
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Table 5.1. Average daily arsenic water consumption

Arsenic dose

Average daily arsenic

Average daily arsenic

water consumption for

water consumption for

post-weaning mouse (7- nursing mouse
10 weeks old)

4.9 ppm As

6.3 mL water/day/mouse

17.7 mL water/day/mouse

1 ppm As

5.7 mL water/day/mouse

NO

ApoE-1- mice were maintained on tap water (control) or exposed to drinking water
containing sodium arsenite (4.9 or 1 ppm arsenic) prenatal or "whole-life" for the
indicated period of time. NO is data not measured.
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Table 5.2. Effects of arsenic exposure on body weight

Arsenic

Age (week)

Unexposed

dose

4.9 ppm As

1 ppm As

Prenatal only

"Whole-life"

expo

expo

10

28 ± 1 9

24 ± 1 9 *

26 ± 1 9

16

28 ± 1 9

ND

28 ± 1 9

16

28 ± 1 9

27 ± 1 9

27 ± 0.4 9

24

30 ± 19

28 ± 1 9

N/A

ApoE-1- mice were maintained on tap water (control) or exposed to drinking water
containing sodium arsenite (4.9 or 1 ppm arsenic) prenatal or "whole-life" for the
indicated period of time. ND is data not measured. N/A is no mice at this age in
exposure group. Values are expressed as mean ± SEM. *p<0.05 compared to
control
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atherosclerosis is unknown. Thus, in this study, the effects of lower arsenic
prenatal exposures on atherosclerosis were determined. The data (Fig. 5.1)
show that atherosclerotic lesion formation in aortic arches appeared increased
2.9-fold at age 10 weeks (p<0.12) and 1.9-fold at age 16 weeks (p<0.27) in mice
exposed to 4.9 ppm arsenic. With lower exposure of 1 ppm arsenic, lesion area
was significantly increased 2.3-fold (p<0.05) at 16 weeks. Lesions were primarily
localized in the area of low shear stress. Interestingly, 1 ppm arsenic prenatal
exposure apparently induced more lesion formation than 4.9 ppm arsenic.
However, analysis of aortic tree and arch of 24 week old mice showed no
difference in lesion formation with 1 ppm arsenic exposure.

"Whole-life" arsenic exposure increases atherosclerotic lesion formation

Next, I examined how prenatal arsenic exposure may interact with later life
exposure in inducing atherosclerosis. For these experiments, arsenic exposure
continued throughout gestation (from GD8) and birth, and continued postnatally
until offspring were sacrificed (Protocols C and E). Lesion formation in these
mice was compared with unexposed mice (Protocol A), or mice exposed to
arsenic prenatally only (Protocol B and D). Data are shown in Fig. 5.2. Compared
to unexposed mice, "whole-life" exposure to 4.9 ppm arsenic did not affect lesion
formation at 10 weeks, but increased lesion formation 2.3-fold (p<0.01) in aortic
arches of 16 week old mice. However, compared to mice exposed to 4.9 ppm
arsenic prenatally, "whole-life" arsenic exposure did not enhance lesion formation
at 10 or 16 weeks, but rather appeared to decrease prenatal arsenic-induced
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Figure 5.1. Effects of low dose prenatal arsenic exposure on
atherosclerotic lesion formation. Pregnant ApoE -/- mice were maintained on
tap water (Protocol A) or water containing arsenic at a dose of 4.9 ppm As
(Protocol 8) or 1 ppm As (Protocol D) from GD8-GD18. Offspring were sacrificed
at 10, 16 or 24 week of age and lesion formation was examined in the aortic arch
or aortic tree where indicated . Data are mean ± SEM . *=p<0.05 compared to
unexposed mice
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lesion formation at 10 weeks. Similarly to prenatal arsenic exposure, "whole-life"
arsenic exposure at 1 ppm arsenic increased lesion formation 2.6-fold in the
aortic arches (p<0.02) compared to unexposed 16 week old mice. However,
"whole-life" arsenic exposure did not enhance prenatal arsenic-induced
atherosclerosis. It should be noted that similarly to prenatal arsenic exposures, 1
ppm arsenic "whole-life" exposure appeared to induce more lesion formation than
the higher 4.9 ppm arsenic exposure.

Effects of arsenic exposure on plasma lipids
Next, I examined whether lower arsenic exposure affects plasma lipids.
Compared to unexposed mice, mice exposed to 4.9 ppm arsenic prenatally only
had lower plasma triglycerides (27 % decrease, p<0.05) at 10 weeks, but had
higher plasma cholesterol (26 % increase, p< 0.05) at 16 week (Fig. 5.3 A). On
the other hand, mice with 4.9 ppm arsenic "whole-life" exposure had 27 % lower
plasma cholesterol (p<0.001) compared to unexposed mice, and 31 % lower
plasma cholesterol (p<0.001) compared to prenatal arsenic-exposed mice at 10
weeks. Similarly, compared to prenatal arsenic-exposed 16 week old mice, mice
with 4.9 ppm arsenic "whole-life" exposure had 25 % lower plasma cholesterol
(p<0.008). At 16 weeks of age, mice with lower arsenic exposure of 1 ppm
arsenic prenatal only had 42 % lower plasma triglycerides (p<0.05) compared to
unexposed mice (Fig. 5.3 B), while mice with 1 ppm arsenic "whole-life" exposure
had 38 % higher plasma cholesterol compared to prenatal exposure (p<0.0002).
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Figure 5.2. Effects of "whole-life" arsenic exposure on atherosclerotic
lesion formation. Pregnant ApoE -/- mice were maintained on tap water
(Protocol A) or water containing arsenic at a dose of 4.9 ppm As (Protocol C) or 1
ppm As (Protocol E) continuously from GOB to birth , and pups were exposed
postnatally until day of sacrifice at 10 or 16 weeks of age . Lesion formation was
examined in the aortic arch . Data are mean ± SEM . *=p<O.05 compared to
unexposed mice.
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Figure 5.3. Effects of arsenic exposure on plasma lipids. ApoE -/- mice were
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age , and plasmas were analyzed for lipid concentrations. Data are mean ± SEM .
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arsenic-exposed mice.
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Effects of arsenic exposure on plasma cytokine/chemokine expression
Pro-inflammatory cytokines and chemokines playa role in atherogenesis.
Therefore, I determined the effect of arsenic exposure on the expression of
plasma cytokines and chemokines. Mice with prenatal arsenic exposure at high
exposure of 49 ppm arsenic showed increased plasma expression of KG
(p<0.02) and VEGF (p<0.02) at 3 week; and IL-6 (p<0.05) and KG (p<0.05) at 10
weeks compared to unexposed controls (Fig. 5.4 A). However, mice with lower
exposures of 4.9 and 1 ppm arsenic prenatal only did not show altered
expression of any of the plasma cytokines/chemokines measured (Fig. 5.4 8).
On the other hand, mice with 4.9 ppm arsenic "whole-life" exposure had
increased plasma

IL-1~

p<0.05), KG (p<0.04) and MGP-1 (p<0.03) at 10 weeks

while only IL-6 (p<0.04) was increased at 16 weeks compared to unexposed
mice (Fig. 5.5 A). Mice exposed "whole-life" to much lower arsenic exposure of
1ppm arsenic did not show altered expression of plasma cytokines/chemokines
at age 16 weeks (Fig. 5.58).
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Figure 5.4. Effects of prenatal arsenic exposure on plasma
cytokine/chemokine expression. Plasmas from mice exposed to 49 , 4.9 or 1
ppm arsenic prenatal were analyzed for cytokine/chemokine expression using an
immunoassay multiplex bead based kit (Millipore Corporation , Billerica , MA) on a
Luminex 200TM IS (Luminex Corporation , Austin TX) . Data are mean ± SEM .
*=p<O.05 compared to unexposed mice
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Figure 5.5. Effects of "whole-life" arsenic exposure on plasma
cytokine/chemokine expression. Plasmas from mice with "whole-life" arsenic
exposure at 4.9 or 1 ppm arsenic exposure were analyzed for
cytokine/chemokine levels using an immunoassay multiplex bead based kit
(Millipore Corporation , Billerica , MA) on a Luminex 200™ IS (Luminex
Corporation , Austin TX) . Data are mean ± SEM . *p<0 .05 compared to unexposed
mice
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Discussion
Accumulating evidence from epidemiological studies shows that arsenic
exposure causes CVD and mortality (States et aI., 2009b). These
epidemiological studies have been confirmed in animal models, with both
prenatal (Srivastava et aI., 2007) and postnatal (Lemaire et aI., 2011; Srivastava
et aI., 2009) arsenic exposures reported to increase atherosclerosis which
underlies most CVD. In addition, CVD showed arsenic dose-response in
humans (Chen et aI., 1996; Chen et aI., 2011). Similarly, in animal models,
postnatal arsenic exposure at 49,4.9 and 1 ppm arsenic exposure produced a
dose-dependent increase in atherosclerotic lesion formation in ApoF'- mice, with
disease incidence increasing with higher arsenic exposures (Srivastava et aI.,
2009). However, a more recent study showed an inverse dose-response effect of
arsenic-induced atherosclerosis. In this study (Lemaire et aI., 2011, mice
postnatally exposed to much lower arsenic exposure (0.2 ppm arsenic) had more
atherosclerotic lesion formation than mice with moderate exposures (1 ppm
arsenic).
Whereas there is significant knowledge on the dose-response effect of postnatal
arsenic exposures on the induction of atherosclerosis, little is known how lower
doses of prenatal arsenic exposure may modulate atherogenesis. Thus, in this
study, the effects of lower arsenic prenatal exposures on atherosclerosis were
determined. This study for the first time has shown that prenatal arsenic
exposure appears to induce more atherosclerosis at lower exposures than at
higher exposures. The increase in lesion formation in the aortic arch appeared
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greater in mice with 1 ppm arsenic prenatal exposure than those with 4.9 ppm
arsenic exposure. These data are consistent with the postnatal arsenic study
reported by (Lemaire et aI., 2011), but are different with the (Srivastava et aI.,
2009) study. This difference may be attributed to the difference in life stage
exposures, prenatal versus postnatal exposures.
Whereas circulating cholesterol and triglycerides are risk factors for developing
atherosclerosis, ischemic heart disease in humans associated with arsenic
exposure was reported to be independent of alterations in serum lipids (Hsueh et
aI., 1998). Similarly, in animal models, both prenatal and postnatal arsenicinduced atherosclerosis is not associated with altered plasma cholesterol.
However, triglyceride levels have been reported to be altered by arsenic
exposures associated with increased atherosclerosis. Both prenatal (Srivastava
et aI., 2007) and postnatal (Srivastava et aI., 2009) arsenic-induced
atherosclerosis were associated with significant decrease in plasma triglyceride.
However, another study (Lemaire et aI., 2011) reported an increase in plasma
triglycerides associated with arsenic-induced atherosclerosis. In the current
study, lower arsenic exposure prenatal significantly decreased plasma
triglycerides at 10 weeks (4.9 ppm arsenic) and 16 weeks (1 ppm arsenic) which
is consistent with earlier report with 49 ppm arsenic exposure (Srivastava et aI.,
2007). These data suggest that despite a significant decrease in plasma
triglycerides, prenatal arsenic exposure at lower doses increases lesion
formation. Whereas plasma triglycerides were not altered with 4.9 ppm arsenic
exposures prenatal when mice were 16 weeks of age, plasma cholesterol was
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significantly increased. This increased plasma cholesterol was surprising
because it is the first reported observation with arsenic-induced atherosclerosis.
The increase in plasma cholesterol caused by arsenic exposure might be
contributing to the accelerated atherogenesis.
Collectively, these experimental data along with human data reporting the
occurrence of myocardial infarction in infants exposed to arsenic (Rosenberg,
1973; Rosenberg, 1974), suggest that infants might be at high risk to the
atherogenic effects of arsenic even at lower exposures.
Prenatal exposure to arsenic induces atherosclerosis later in life. However, it is
clear that human environmental exposure to inorganic arsenic occurs during the
entire life span, and not limited to the prenatal period. How prenatal arsenic
exposure may modulate exposure that occurs after gestation and during entire
life span ("whole-life") has been unclear. According to the predictive adaptive
response (Gluckman and Hanson, 2004), prenatal arsenic exposure will protect
against later life exposure due to adaptations made by the fetus in preparation for
postnatal life. For example, gestational high-fat diet results in endothelial
dysfunction and hypertension in adult rat offspring (Khan et aI., 2004; Khan et aI.,
2003). However, if the offspring are also maintained on high-fat diet after birth,
endothelial dysfunction although not the hypertension is prevented (Khan et aI.,
2004). Conversely, in transplacental arsenic-induced carcinogenesis mouse
model, "whole-life" arsenic exposure resulted in higher tumor incidence than
prenatal only exposures (Tokar et aI., 2011), thus suggesting that late life
exposure enhanced prenatal arsenic exposure. In the current study, similar to
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prenatal exposures, atherosclerosis appears to be increasing with decreasing
doses of "whole-life" arsenic exposures. However, when compared to prenatal
only exposure, "whole-life" arsenic exposure at any dose did not alter prenatal
arsenic-induced atherosclerosis. In addition, "whole-life" arsenic exposure did not
alter plasma triglycerides when compared to unexposed groups, but decreased
plasma cholesterol (at 4.9 ppm arsenic, 10 weeks) similar to prenatal exposure.
However, "whole-life" arsenic exposure altered some of the plasma effects
induced by prenatal exposure. For example, "whole-life" arsenic exposure
attenuated prenatal arsenic-induced plasma cholesterol (4.9 ppm arsenic, 16
week), and elevated prenatal arsenic-decreased triglyceride (1 ppm arsenic, 16
week) to control levels. These plasma lipid data suggest that "whole-life" arsenic
exposures may mediate atherogenesis through mechanisms which might be
different from prenatal exposure. Together, these compelling data suggest that
once atherogenesis is initiated by arsenic exposure prenatal, the disease
outcome is independent on further exposures occurring later in life. Thus, there is
an apparent need to protect pregnant mothers from arsenic exposures even in
populations with very low exposure levels such as the United States in order to
prevent elevated CVD.
Inflammation plays a key role in atherogenesis. Atherogenesis requires local
chemokine production for the migration of leukocytes. Furthermore, vascular
cells (endothelial cells, monocytes/macrophages, and smooth muscle cells)
involved in atherogenesis secrete chemokines and pro-inflammatory cytokines.
The chemokine IL-8 (human ortholog of mouse KC) is an angiogenic factor (Koch
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et aL, 1992), and a chemotactic factor for vascular smooth muscle cells (Yue et
aL, 1993), T-cells (Lloyd et aL, 1996), and monocytes (Gerszten et aL, 1999).
Arsenic is reported to induce the expression of IL-8 in human aortic endothelial
cells (Simeonova et aL, 2003). IL-6 is a pro-inflammatory cytokine and is
recognized as a marker for vascular inflammation (Kleemann et aL, 2008). In
addition, circulating IL-6 is an independent risk factor coronary artery disease
(Luc et aL, 2003), and increased IL-6 expression in plaques strongly correlates
with plaque instability and rupture (Biasucci et aL, 1996). MCP-1 is important in
the trafficking of macrophages. Genetic deletion of MCP-1 and IL-6 in mice
decreased atherosclerotic lesion formation (Gu et aL, 1998; Schieffer et aL,
2004). IL-113 has pro-atherogenic properties associated with upregulation of
endothelial adhesion molecules, and activation of macrophages and vascular
cells (Ait-Oufella et aL, 2011). VEGF is an angiogenic factor, can function as an
inflammatory cytokine, promoting lesion formation and plaque instability (Holm et
aL, 2009). Therefore, I determined the effects of prenatal and "whole-life" arsenic
exposures on plasma cytokine/chemokine expression. I observed that both
exposure types increased specific plasma cytokines/chemokines which include
KC (murine ortholog of IL-8), IL-6, IL-113, MCP-1 and VEGF. The
cytokine/chemokine expression was age-, dose-, and exposure type-specific. In
addition, whereas prenatal arsenic exposure alone altered cytokine expression
only at high exposure (49 ppm arsenic), "whole-life" exposure altered cytokine
expression at lower exposure levels (4.9 ppm arsenic). These data are consistent
with epidemiologic data (Wu et aL, 2003) showing increased plasma IL-6
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concentrations in arsenic exposed humans, and with animal studies (Srivastava
et aI., 2009) showing arsenic-induced vascular and circulating concentrations of
MCP-1 and IL-6. Furthermore, prenatal arsenic exposure is reported to alter the
gene expression profile (including IL-8 and

IL-1~)

in newborn cord blood (Fry et

aI., 2007). Collectively, my experimental data along with reported data suggest
that arsenic-induced inflammation plays an important role in accelerating
atherogenesis.
In summary, this study indicates that the induction of atherosclerosis appears to
be increasing with decreasing arsenic levels of prenatal exposures.
Atherosclerosis induction by arsenic exposure is associated with alterations in
plasma cholesterol and triglycerides. Furthermore, "whole-life" exposures also
result in increased lesion formation similar to prenatal exposure when compared
with controls. Interestingly, atherosclerotic lesion area was the same in both
prenatal only and "whole-life" arsenic exposures, suggesting only the prenatal
exposure counts. However, there appear to be an interaction- but not an additive
effect between prenatal only and later life exposures. Circulating
cytokine/chemokine expression showed dose-specific increase, thus indicating
inflammation. Our observations suggest that disease may be even higher at
lower exposures. Therefore, it will be important to examine the effect of prenatal
arsenic exposure at much lower doses (doses<1 ppm arsenic). Future studies will
determine lesion formation in aortic valves and also determine exosomal Hsp70
expression.
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CHAPTER VI

General conclusions and future studies
Inorganic arsenic has been considered a hazardous compound for many years
because of its deleterious effects on human health worldwide. The most
established toxic effect of arsenic on human health is cancer, with arsenic
reported to cause lung, liver, skin, and bladder cancer. However, it is also now
accepted that arsenic exposure, both prenatally and postnatally also causes
atherosclerosis which underlies most CVD in humans and in animal models.
Despite the strong evidence implicating arsenic exposure in the development of
CVD, it is still unclear how arsenic mediates disease progression. The first part of
this study focused more on the liver as the source of atherogenic stimulus, based
on several reports of how the risk of CVD increases with liver disease. A major
finding in this dissertation is that prenatal arsenic exposure causes liver damage
several weeks later during postnatal life in ApoF'- mice. This liver damage was
characterized by increased plasma ALT and AST liver enzymes, and IL-6
expression, with no major changes in liver histology and hepatic inflammation.
These findings are similar to earlier reports showing induction of liver damage by
chronic postnatal arsenic exposures in humans (Mazumder, 2005) and animal
models (Arteel et aI., 2008; Waalkes et aI., 2003; Santra et aI., 2000; Wu et aI.,
2008). However, what is different and new about the current study is that.
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whereas liver damage was induced by chronic postnatal arsenic exposures for
several months in earlier studies, liver damage was induced by a relatively
shorter 10 day prenatal exposure in the current study. The liver damage was
manifested several weeks (10 and 24 weeks) after arsenic exposure is removed.
In addition, this is the first study showing the induction of liver damage by arsenic
exposure in an atherosclerosis animal model as opposed to reported studies
performed in other mice strains such as C57B1/6J, C3H and BALB/c. The
induction of liver damage by prenatal arsenic exposure in the ApoF'-mice is a
significant finding because these findings confirm earlier epidemiological reports
(Brea et aI., 2005; Targher et aI., 2004; Targher et aI., 2006) showing that the risk
of developing atherosclerosis increases with liver disease. In addition, elevated
plasma AL T and AST are independent risk factors for atherosclerosis,
independent of traditional risk factors such as metabolic syndrome (Adibi et aI.,
2007; Bellentani et aI., 2008; Schindhelm et aI., 2007). However, this study
shows that prenatal arsenic exposure does not sensitize the liver to enhanced
liver toxicity owing to LPS, which is different from earlier reports of increased
sensitivity to liver damage owing to LPS by chronic postnatal arsenic exposures
(Arteel et aI., 2008). The lack of sensitivity to liver damage by prenatal arsenic
exposure can be attributed to the difference in life-stage exposure, prenatal
versus chronic postnatal exposures. These differences suggest that additional
postnatal arsenic exposures will be needed to sensitize the liver to enhanced
liver damage caused by LPS. A weakness in the LPS study is that only the 24 h
time-point was analyzed after the LPS challenge, considering that the induction
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of cytokines (hepatic or plasma) is temporal. In the future, mice should be
euthanized at different time points (e.g. 0, 6 12 and 24 h) post LPS injection in
order to avoid missing the peak levels of cytokine expression as was probably
the case with the current study.
Another major finding in this dissertation is the delayed temporal induction of
Hsp70 in the livers (3-10 weeks) of mice exposed to arsenic prenatally, thus
indicating stress. This finding is similar to earlier reports showing increased
Hsp70 expression in animal tissues following arsenic exposures (Andrew et aI.,
2007; Han et aI., 2005; Liu et aI., 2001). However, what is different and new and
thus a strength in the current study is that whereas the expression of Hsp70 was
determined only at one time point or age immediately following arsenic exposure
in the earlier studies, the current study investigated Hsp70 expression during
prenatal and postnatal development following prenatal arsenic exposure. An
absence in the induction of Hsp70 expression immediately following arsenic
exposure (at GD18) in the current study indicates Hsp70 expression is not
sufficient to be used as a biomarker of arsenic exposure as proposed by earlier
studies (Del Razo et aI., 2001; Han et aI., 2005). In addition, Hsp70 induction
observed at 3-10 weeks of age indicates a critical window of enhanced sensitivity
to other environmental factors. For example, if the mice are challenged with LPS
during this window, they might show increased sensitivity to liver damage. The
Hsp70 induction by prenatal arsenic exposure was associated with increased

Hsp70 DNA methylation in the body of the gene (indicating an epigenetic effect),
and underlying mechanism of induction is likely by increased mRNA stability as
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indicated by decreased miRNA expression. However, future studies are needed
to confirm the regulation of Hsp 70 by the decreased miRNAs. This finding also
suggests that the stressed liver cells can release excess Hsp70 in to circulation
which can activate macrophages and thus promote atherogenesis as have been
earlier reported (Lu and Kakkar, 2010). However, a weakness in the Hsp70
expression study is the lack of evidence of increased plasma exosomal Hsp70
expression associated with the accelerated atherosclerosis. Therefore, future
studies are required to determine exosomal Hsp70 expression.
Taken as a whole, these data therefore indicate that the deleterious effects of
prenatal arsenic exposure on the liver can be contributing to the increased
atherosclerosis observed in the ApoF'- mouse model.
The second part of this dissertation determined the effects of prenatal arsenic
exposure on atherosclerosis and how later life arsenic exposure modifies
exposures prenatally. A major finding in this study is that atherosclerotic lesion
formation appears to be increasing with decreasing doses of prenatal arsenic
exposure. This finding is different from earlier reports of decreasing lesion
formation with decreasing doses of postnatal arsenic exposures (Srivastava et
aI., 2009). The difference in dose-response lesion formation between postnatal
and prenatal arsenic exposures might be attributed to the difference in life-stage
of exposure. The prenatal exposure interacts with postnatal exposure to change
the response. These data indicate that differences exist between prenatal arsenic
exposure and postnatal exposures in the induction of atherosclerosis.
Furthermore, "whole-life" arsenic exposure did not enhance lesion formation
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induced by prenatal exposures. Absence of lesion enhancement by later life
exposure is a significant finding and a strength in this study, and suggests that
only the prenatal exposure counts. In the future, the aortic valves will also be
analyzed for lesion formation, to correlate with lesion formation in the aortas.
Both exposure types increased plasma cytokines and chemokines related to
CVD, indicating inflammation, which is a risk factor contributing to
atherosclerosis. These data are quite compelling and indicate that gestation is
indeed a very sensitive period of development and toxic exposures to the
intrauterine environment can result in deleterious effects that lead to diseases
later in life. These data indicate that exposure to arsenic prenatally initiates
atherogenesis, which manifest later in life whether or not there is additional latelife exposure. A weakness in this part of the study is that only 2 arsenic doses
(4.9 and 1 ppm arsenic) were determined, and thus not enough to conclude on
the dose-response curve. In addition, the current study did not include postnatal
only exposures to make direct comparisons with prenatal and "whole-life"
exposures. Further studies are required to determine the arsenic effects at lower
exposures «1 ppm arsenic), and also to determine if there is indeed a threshold
exposure level. Indeed, postnatal arsenic exposure was reported to induce more
atherosclerotic lesion formation at 0.2 ppm arsenic than at 1 ppm arsenic
(Lemaire et aI., 2011). This report suggests that prenatal arsenic exposure at
exposures < 1 ppm arsenic is likely to induce more atherosclerotic lesion
formation. Further studies are also needed to determine if the prenatal arsenic
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effects on atherosclerosis can be reversed by supplementing prenatal arsenicexposed mice with anti-inflammatory therapies during their postnatal life.
In conclusion, mechanisms of prenatal arsenic exposure-induced atherosclerosis
include subtle but significant hepatic stress and damage, and increased systemic
inflammation.
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APPENDIX
List of Abbreviations
AAlAC

Association for Assessment of laboratory Animal care

ALP

Alanine phosphatase

AlT

Alanine amino transferase

AN OVA

Analysis of Variance

ApoE-1- mice

Apolipoprotein E knockout mice

AST

Aspartate amino transferase

bp

base pair

CAE

Chloroacetae esterase

CO 2

carbon dioxide

CpG

Cytosine guanine linear dinucleotide

CVD

Cardiovascular disease

DNA

Deoxyribonucleic acid

DTT

Dithiothreitol

EGTA

Ethylene glycol tetraacetic acid

ECl

Enhanced chemiluminescence

EDTA

Ethylene diamine tetraacetic acid

EPA

Environmental Protection Agency

GD

Gestation day
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HCl

Hydrogen chloride

H/E

Hematoxylin/Eosin

HRP

Horse radish peroxidase

Hsc70

Heat shock cognate 70

Hsf1

Heat shock factor 1

Hsp70

Heat shock protein 70

HSPA

Heat shock protein family A

ICP-MS

Inductively-coupled plasma mass spectrometry

Il-6

Interleukin-6

IP

Intraperitoneal

IVC

Inferior vena cava

KC

Kupffercell

lPS

Lipopolysaccharide

NPC

Non parenchymal cell

MCl

Maximum contaminant limit

MCP-1

Monocyte chemoattractant protein-1

mRNA

messenger ribonucleic acid

miRNA

Micro ribonucleic acid

NaAs0 2

Sodium arsenite

NaCI

Sodium chloride

NaF

Sodium flouride

NAFlD

Non alcoholic fatty liver disease

Na3V04

Sodium orthovanadate
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Nrf2

Nuclear factor-2 erythroid related factor-2

OCT

Optimal cutting temperature

PBS

Phosphate buffered saline

PC

Parenchymal cell

PCR

Polymerase chain reaction

PMSF

Phenylmethylsulphonylfluoride

RIPA

Radioimmunoprecipitation assay

RNA

Ribonucleic acid

SAM

S-adenosyl methionine

SC

Stellate cell

SEC

Sinusoidal endothelial cell

SOS

Sodium dodecyl sulfate

SOS-PAGE

Sodium dodecyl sulfate - polyacrylamide gel electrophoresis

TE

Tris- ethylene diamine tetraacetic acid

TNF-a

Tumor necrosis factor alpha

US

United States

USEPA

United States Environmental Protection Agency

VEGF

Vascular endothelial growth factor

WHO

World Health Organization
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